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Mycoplasma bovis poses a significant threat to the Canadian beef industry, particularly 
the feedlot sector where it is associated with bovine respiratory disease (BRD) and chronic 
pneumonia and polyarthritis syndrome (CPPS). Furthermore, its characteristic chronic infections 
which are refractory to antimicrobials results in animal welfare and economic concerns. 
Currently, antimicrobials are the primary therapeutic option for treatment and control of M. bovis 
infections due the absence of a vaccine. This is salient given the global concern regarding 
antimicrobial use (AMU), antimicrobial resistance (AMR), and increased levels of AMR 
reported for M. bovis worldwide.  
Due to the current reliance on antimicrobials for prevention, control, and treatment, 
continual surveillance of antimicrobial susceptibility is crucial for antimicrobial stewardship and 
therapeutic treatment of M. bovis related disease. Not only is there a reduced arsenal of 
antimicrobials for the prevention, control and treatment of M. bovis, but its fastidious nature and 
difficulties associated with culturing emphasize a need for antimicrobial susceptibility testing 
(AST) using rapid, accurate, molecular methods. Whole genome sequencing (WGS) provides a 
plethora of information that can be interrogated to investigate different aspects of M. bovis 
pathogenesis, including antimicrobial susceptibility and virulence, such as multilocus sequence 
typing (MLST) for classifying bacterial strains. In conclusion, an epidemiological, genotypic and 
phenotypic investigation into the antimicrobial susceptibility of M. bovis will contribute to the 
body of knowledge needed to assist in evidence-based decisions for the treatment and control of 
M. bovis infections in cattle and provide the rationale for the studies outlined in this thesis. 
M. bovis isolates derived from western Canadian feedlot cattle sampled over a 12-year 
period (2006 - 2018) were used to address three objectives: 1), describe the AMU and AMR 
profiles of isolates derived from M. bovis mortalities in feedlot cattle (Chapter 2); 2), investigate 
the genotypic basis for macrolide resistance by assessing single nucleotide polymorphisms 
(SNPs) in 23S rRNA gene alleles and ribosomal proteins L4 and L22 (Chapter 3); and 3), assess 
the application of four genotyping methods for M. bovis (Chapter 4). M. bovis was cultured from 
deep nasopharyngeal swabs as well as lung and joint tissue from western Canadian feedlot cattle 
(cattle, n = 134; isolates, n = 183). Antimicrobial susceptibility testing (AST) was performed 
using a microbroth dilution assay and a customized panel of nine antimicrobials, representing 
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four drug classes, most commonly administered to feedlot cattle in western Canada. 
Furthermore, M. bovis isolates (n = 129) underwent WGS utilizing Illumina technology.  
Although M. bovis isolates were derived from western Canadian feedlot cattle, Chapter 2 
was not intended as a representative study of western Canadian feedlots but rather to provide 
context on AMR and AMU in feedlots and the background of the cattle and isolates represented 
in this thesis. In chapter 2, over 90% of cattle had received antimicrobial metaphylaxis, with 
tulathromycin accounting for 94.2 % of treatments. On average, cattle received three 
antimicrobial classes prior to dying of a mycoplasma-related pneumonia. The most commonly 
administered classes were macrolides (93.2%), phenicols (78.4%), and fluoroquinolones 
(67.6%). Isolates had the least resistance to florfenicol, with 89.9% classified as susceptible.  
Nearly all isolates were resistant to all five macrolides (gamithromycin, tildipirosin, tilmicosin, 
tulathromycin, tylosin) assessed. The study described in Chapter 3 found that mutations in both 
domains II and V of the 23S rRNA gene alleles were found to be associated with resistance to all 
five macrolides. Isolates with a mutation in domain II and the L4 and L22 ribosomal proteins 
were also resistant to all macrolides, except tulathromycin. Lastly, in Chapter 4, four in silico 
genotyping methods were applied to M. bovis isolates and the Simpson’s Diversity Index (D) 
was used to assess resolution of each method. MLST had the lowest resolution (D=0.932) but 
was the easiest to implement and apply; contrastingly, whole genome single nucleotide variant 
(wgSNV) yielded the highest resolution (D=1.000), but also involved the most complicated 
analysis. Application of core genome MLST (cgMLST) and core genome SNV (cgSNV) had a 
similar resolution of 0.987 and 0.984, respectively. No association between genotype and 
phenotype was resolved. 
Overall, M. bovis isolates in western Canadian feedlot cattle were predominately 
susceptible to a single antimicrobial, florfenicol, and commonly administered macrolides for 
BRD metaphylaxis. AMR was observed to all macrolides tested, and the accumulation of SNPs 
in genes associated with macrolide resistance correlated to a macrolide resistant phenotype using 
AST. Despite being unable to associate genotype and phenotype, the typing methods yielded 
comparable phylogenetic relationships. Furthermore, the diversity of strain types highlighted the 
structure of the Canadian cattle industry and how cattle are procured for western Canadian 
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1 INTRODUCTION AND LITERATURE REVIEW 
1.1 Introduction 
Mycoplasma bovis is considered to be one of the smallest self-replicating organisms, with 
its gene content bordering on the minimum number to sustain bacterial life [1]. M. bovis is 
associated with bovine respiratory disease (BRD) and chronic pneumonia and polyarthritis 
syndrome (CPPS) in feedlot cattle [2-4]. In a feedlot, death within days to weeks post-arrival is 
commonly attributed to BRD; whereas, death after a month is attributed to CPPS [3]. The time 
cattle spend in a feedlot being fed is referred to as days on feed (DOF) [5]. 
Mycoplasmosis is both an economic and animal welfare concern for Canadian feedlot 
producers. The economic impact of M. bovis results from reduced weight gain, increased 
treatment costs, and death losses [6,7]. Concerns for welfare arise because M. bovis is associated 
with chronic infections, such as CPPS, that respond poorly to antimicrobial treatment [6]. 
Furthermore, polyarthritis is particularly debilitating and painful manifestation of mycoplasmosis 
resulting in lameness, leading to decreased feed consumption and weight loss [4,8]. Poor 
response to treatment can also lead to antimicrobial resistance in other BRD pathogens [7]. This 
is of particular importance as BRD is a multifactorial infection associated with other bacterial 
pathogens, particularly Manheimmia haemolytica, Pasteurella multocida, and Histophilus somni 
[9]. Further compounding the impact of M. bovis, is the fact that antimicrobial resistance (AMR) 
within Canada [10-13] and worldwide [14-22] is increasing. 
AMR is a global concern, spanning both human and animal microbial species. The Public 
Health Agency of Canada (PHAC) has outlined three areas of focus to respond to AMR in 
Canada: surveillance, stewardship and innovation [23]. In animal health, antimicrobial 
stewardship is a primary responsibility of veterinary professionals [24]. Antimicrobial 
stewardship is predicated on prudent use guidelines for antimicrobial use (AMU) [25]. This 
thesis focuses on surveillance and stewardship of antimicrobials through antimicrobial 
susceptibility testing (AST), AMU, genotypic correlation to AMR and population structure of M. 
bovis in western Canadian feedlot cattle. Furthermore, investigations on AMR in M. bovis are 
crucial to reducing the welfare and economic impact of BRD and CPPS on feedlot cattle.  
The literature review in Chapter 1 is intended to introduce myoplasmosis, specifically the 
impact of M. bovis related disease in cattle in the context of the Canadian Beef Industry and the 
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practices associated with finishing cattle in a western Canadian feedlot. A more in-depth 
description of M. bovis is presented focusing on the details relevant to the epidemiological, 
phenotypic and genotypic studies undertaken in this thesis. 
1.2 Mollicutes and Mycoplasmosis 
 Mycoplasmas belong to the class Mollicutes and are characterized by not having a cell 
wall (Figure 1.1), making them a gram negative bacterium. However, they evolved from a gram 
positive ancestor, and have highly reduced genomes that possess nearly the minimum gene 
content needed to sustain independent bacterial life [26]. A consequence of a reduced genome is 
the absence of genes for some biosynthetic pathways [27]. The absence of these complete 
biosynthetic pathways makes Mycoplasma spp. reliant on exogenous sources of biosynthetic 
products and suggests a close association with their host. These exogenous dependencies make 
Mycoplasma spp. difficult to culture, with different Mycoplasma spp. having different nutrient 
requirements [28]. The absence of a cell wall and some biosynthetic pathways make 
Mycoplasma spp. intrinsically resistant to antimicrobials such as β-lactams and trimethoprim that 
target peptidoglycan and folic acid synthesis, respectively [29]. Additionally, mycoplasmas are 
considered to be fast evolving, due to their exploitation of spontaneous mutagenesis [26]. 
Mycoplasma spp. include both human and veterinary agents, with a predilection for colonizing 
mucosal surfaces in the respiratory and reproductive tracts [30], and are capable of intracellular 





Figure 1.1 Schematic of the cell wall structure of gram negative and gram positive bacteria. Mollicutes, such as Mycoplasma 





Mycoplasmosis is a common disease of people and food production animals such as 
chickens, turkeys, pigs, and cattle. There are multiple Mycoplasma spp. that affect different 
animals, but regardless of the host infections within these different species, mycoplasma 
infections commonly manifest as clinical manifestations involving the mucosal surfaces within  
joints, respiratory or reproductive tracts [30]. Mycoplasma infections in veterinary medicine can 
be particularly detrimental due to their welfare and economic impact. In poultry, Mycoplasma 
gallisepticum and Mycoplasma synoviae are associated with infections of the respiratory tract 
and joints, respectively [29]. In piglets, Mycoplasma hyorhinis and Mycoplasma hyosynoviae are 
associated with polyserositis and arthritis, and Mycoplasma hyopneumoniae is associated with 
chronic pneumonia [29]. 
 In cattle, Mycoplasma spp. are associated with various ailments such as: mastitis 
(Mycoplasma bovis, Mycoplasma bovigenitalium, Mycoplasma californicum); arthritis (M. 
bovis); pneumonia (Mycoplasma mycoides subsp. mycoides (small colony), M. bovis, 
Mycoplasma dispar, Mycoplasma canis, M. californicum); and reproductive infections (M. bovis, 
M. bovigenitalium) [8]. M. mycoides subsp. mycoides is highly virulent and the causative agent 
of contagious bovine pleuropneumonia (CBPP) [32]. CBPP is a reportable disease to the World 
Organization for Animal Health (OIE) and was eradicated in Canada in 1876 [33]. However, 
CBPP is still endemic in sub-saharan Africa [34]. This organism is of concern in North America 
because infections caused by M. bovis and M. mycoides subsp. mycoides are difficult to 
differentiate on gross postmortem examination. M. bovis is not specific to cattle, as it is also 
associated with pneumonia in bison [35,36]. Generally, M. bovis infections in all species tend to 
be chronic and frequently refractory to antimicrobial therapy [6], which compounds the welfare 
and economic impacts of this bacterium on the beef industry. 
1.3 Overview of Canadian Beef Industry 
In Canada, as well as in the United States, the beef industry consists of three main 
sectors: cow-calf, stocker (also known as backgrounders), and feedlot [37]. Cow-calf operations 
comprise the bulk of the beef sector, providing a supply of stocker and feedlot cattle. Cows or 
heifers are typically bred in the summer and following a nine month gestation period have their 
calves the following spring. After weaning in the fall, the calves go either directly into feedlots, 
or they may be backgrounded. 
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Cattle can arrive in a feedlot via two different ways: ranch direct or auction mart. Ranch 
direct means that a group of cattle are purchased and transported directly from a cow-calf 
operation to a backgrounder. For cattle that arrived via an auction mart, cattle are transported 
from the home ranch to the auction mart, commingled with cattle from other ranches to form 
uniform groups, sold and then shipped to a feedlot. Cattle can also arrive at the same feedlot, via 
different auction marts or ranches. Western Canadian feedlots also source cattle from the United 
States. 
Calves can enter the feedlot in three general ways. Firstly, calves can enter the feedlot 
directly following weaning in the fall. Fall-weaned calves are born in the spring, spend the 
summer on pasture with their dam and are shipped to feedlots for backgrounding using a forage-
based diet and finishing using a grain-based diet. The next two cohorts of calves utilize 
backgrounding prior to entry. Calves weaned in the fall can be maintained, often by cow calf-
producers, until the following spring when they enter into the feedlot. Lastly, calves can be 
maintained over winter and then grazed on pasture over the summer before entering the feedlot 
the following year as a yearling for a shorter finishing period. These stocking operations help to 
maintain a year-round supply of cattle for finishing outside of the peak fall entry. Depending if 
they enter as calves, backgrounded animals, or yearlings, cattle spend approximately 60-200 
days in a feedlot [38]. 
Feedlots are considered an intensive method of finishing cattle. While at the feedlot, 
cattle are sorted into pens of animals of uniform size, sometimes more than once and fed rations 
with increasing proportions of grain until the animal reaches its finished weight of approximately 
600-700kg [39]. Once a group of animals has reached a uniform target weight in the feedlot they 
are sold and transported to a packer. At the packer the animals are inspected during slaughter and 
processing before any meat products enter the food chain. 
1.4 Mycoplasma bovis in the feedlot 
Globally, M. bovis is regarded as the most ubiquitous mycoplasma of cattle [40]. M. bovis 
was first isolated in North America the 1960’s in the United States from a case of mastitis [41], 
and has since spread worldwide through animal movement [40]. It is associated with chronic 
infections and lameness [3,6] causing pain and suffering and hence these infections are 
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considered an animal welfare issue. Additionally, economic impacts arise due to reduced weight 
gain, increased treatment costs, and death [6,7,40]. 
BRD is the most common morbidity and mortality in feedlots [42]. Clinical signs of 
undifferentiated bovine respiratory disease can include difficulty breathing, depression, anorexia, 
fever, and evidence of pneumonia [32]. Various differential diagnoses of bovine respiratory 
diseases exist, with differences identified based on their underlying etiology.  
1.4.1 Bovine Respiratory Disease (BRD) 
BRD is caused by multiple microbial agents and is attributed to causing 70-80% of 
morbidities in feedlot cattle and 40-50% of mortalities in the US cattle industry [43]. Focusing 
on western Canadian feedlot cattle, Brault et al. [44] reported that 39% of approximately 2.6 
million cattle from 2008 to 2012 were classified as ‘high risk’ for BRD.  In addition to M. bovis, 
BRD is a polymicrobial disease with various bacterial and viral etiological agents. These bacteria 
include M. haemolytica, P. multocida, and H. somni; whereas, viral components include bovine 
viral diarrhea virus (BVDV), infectious bovine rhinotracheitis (IBR), parainfluenza 3 (PI-3) and 
bovine respiratory syncytial virus (BRSV) [9]. M. haemolytica causes an acute fibrinous 
pneumonia or acute fatal pneumonia, which is synonymous with classical ‘shipping fever’, 
whereas M. bovis is associated with chronic caseonecrotic pneumonia. BRD typically occurs 
within 14 DOF [32]. Cattle entering the feedlot are classified as high or low risk for BRD, based 
on algorithms taking into account age, source and a range of management factors that can 
influence stress. Age is generally used as a proxy for immune status, with younger animals being 
considered to be less immunocompetent [32]. High risk features include fall-weaned calves that 
arrive at the feedlot via auction, where they have commingled with other cattle. Low risk cattle 
may be backgrounded or preconditioned and/or arrive at the feedlot following a ranch-direct sale. 
Preconditioning is a management practice that encompasses completion of stressful events such 
as weaning, castration, dehorning, and the administration of vaccines, particularly those for 
BRD, in advance of the animals leaving the cow-calf operations [32,43]. The intent of 
preconditioning is to prime the animal’s immune system and reduce stress, which improves the 
overall immune response and decreases the risk of BRD at the time of shipping and commingling 
in auctions and/or feedlots [32]. However, unless ownership of the calves is retained upon entry 
into the feedlot, cow-calf producers are not often compensated for the cost and labour associated 
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with preconditioning, thus reducing the adoption and economic attractiveness of this approach. 
Calves that fall into the high risk category typically receive tulathromycin (i.e., Draxxin®), a 
macrolide, upon arrival; whereas low risk animals often receive no antimicrobial or a lower 
category antimicrobial such as long-acting oxytetracycline [44]. 
Historically, studies on BRD have focused on the bacterial agents M. haemolytica, P. 
multocida, and H. somni. The role of M. bovis in BRD is less clearly defined and it has been 
considered to be opportunistic, a secondary contributor, and a causative agent [3,6,45]. Since all 
BRD bacteria have been isolated from the same lesion, this suggests synergism among these 
bacterial species [3]. The polymicrobial nature of BRD is highlighted in a study by Klima et al. 
[46], where they examined 68 BRD mortalities. Co-infections were observed in 97% of cases, 
with Mannheimia spp., BVDV, and M. bovis present with or without H. somni. This is likely due 
to challenges associated with culturing M. bovis, resulting in it being the least characterized of 
the bacterial members of the BRD complex.  
It is hypothesized that BRD is associated with altering the microbiome of the respiratory 
tract [47]. A recent study by Holman et al. [48], looked at the effect of a single metaphylactic 
treatment with oxytetracycline or tulathromycin on the nasopharyngeal microbiome of beef cattle 
transported to the feedlot. Within days of administration both metaphylactic treatments were 
found to reduce the abundance of BRD-associated agents, including Mycoplasma spp. However, 
at 34 d post-administration of oxytetracycline, Mycoplasma spp. were the predominant BRD 
agents in the nasopharynx. Contrastingly, following tulathromycin metaphylaxis, the 
nasopharyngeal microbiome recovered to resemble the microbiota composition of the control 
animals after 12 d. In an earlier study by Hendrick et al. [10], they observed that calves receiving 
oxytetracycline metaphylactically had a reduced risk of BRD, but an increased risk of arthritis. 
However, the relationship between oxytetracycline and arthritis requires further investigation. 
1.4.2 Chronic Pneumonia and Polyarthritis Syndrome (CPPS) 
CPPS is commonly attributable to a persistent M. bovis infection and characterized by the 
combined afflictions of pneumonia and arthritis that have responded poorly to treatment [49]. 
Arthritis invariably leads to lameness, which further impacts the welfare of cattle by reducing 
their mobility and ability to obtain feed and water [4,8]. These arthritides are generally 
nonresponsive to antimicrobial therapy, but not necessarily due to antimicrobial resistance. Since 
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caseonecrotic lesions form in the lungs and fibrin forms in the joints following M. bovis 
infections [12,50], these pathologies could reduce antimicrobial efficacy due to decreased 
antimicrobial perfusion. Therefore, it can be difficult to control M. bovis infections even if M. 
bovis is susceptible to a given antimicrobial.  
Complicating matters, cattle colonized with M. bovis do not necessarily develop BRD or 
CPPS, rather they can be asymptomatic carriers. Individuals can be intermittent shedders of M. 
bovis without clinical signs of disease [4], making it difficult if not impossible to eradicate this 
pathogen from feedlots. This is exacerbated by cattle arriving at the feedlot from different 
sources and being commingled. In western Canada, Brault et al. [44] reported that nearly 92.9% 
of antimicrobials administered to cattle were for the treatment or prevention of BRD, with nearly 
90% of these through metaphylaxis. The remainder of antimicrobials administered were due to 
acute respiratory disease, lameness, implants or other. Therefore, given the reliance on 
antimicrobials for treatment and prevention of BRD the development of alternatives such as 
vaccines or probiotic supplementation to prevent or treat this disease are of high interest. 
1.4.3 Antimicrobials 
1.4.3.1 Therapeutic Use 
For the purpose of this thesis, the classes of antimicrobials discussed are not exhaustive, 
but rather focus on classes commonly used in western Canadian feedlots to treat BRD and are 
presented in Table 1.1. Feedlot consulting veterinarians are responsible for developing treatment 
protocols specifically for individual feedlots, taking into account risk factors for disease. These 
treatment protocols outline the use of vaccines and antimicrobials, and aid in facilitating 
antimicrobial stewardship. The principles of antimicrobial stewardship include the 
implementation of preventative and management strategies to prevent disease, evidence-based 
selection of antimicrobials, evaluation of antimicrobial efficacy, and judicious antimicrobial use 
to maintain animal health and welfare [51]. Antimicrobials can be administered prophylactically, 
metaphylactically, or therapeutically for the prevention, control, and treatment of diseases, 
respectively [52]. Prophylactic administration of antimicrobials is done as a means of disease 
prevention, based on the anticipation of disease occurring based on historical, clinical or 
epidemiological information [52]. Metaphylaxis is the administration of antimicrobials to reduce 
the incidence, progression, or transmission of an infectious disease that is evident [52], such as 
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when an individual in a cohort of cattle (e.g. pen) shows signs of disease and as a result all cattle 
in the cohort are administered antimicrobials. Therapeutic administration occurs following 
evidence of infectious disease [52]. A common management practice for controlling BRD is for 
cattle to receive metaphylactic antimicrobial therapy upon arrival at the feedlot to reduce the risk 
of respiratory infections [53]. In western Canada, tetracyclines and macrolides are the 
predominant metaphylactically administered antimicrobial classes [44].  
As of December 1, 2018, a veterinary-client-patient relationship (VCPR) is required for 
the prescription and administration of all antimicrobials to livestock in Canada. Additionally, 
label claims for growth promotion have been removed for antimicrobials. The classes of 
antimicrobials commonly used in western Canadian feedlot cattle are macrolides, 
fluoroquinolones, phenicols, and tetracyclines [11,44].  
The World Health Organization (WHO) has categorized medically important 
antimicrobials (MIA) based on two criteria: the limited availability of therapies to treat bacterial 
infections in humans; and their use to treat infections caused by bacteria that could have acquired 
resistance genes from non-human sources [54].  Critically important antimicrobials (CIAs) meet 
both of these criteria; whereas highly important antimicrobials meet either criteria. Important 
antimicrobials do not meet either of these criteria, but are used in human medicine.  On a global 
scale, the WHO lists quinolones and macrolides as critically important, and phenicols and 
tetracyclines as highly important antimicrobials [54].  
Health Canada has also classified antimicrobials based on their importance in human 
medicine and availability of alternative therapies [55]. Category I antimicrobials, are considered 
to be of very high importance with category II, III, and IV being of high, medium, and low 
importance, respectively. In Canada, quinolones and macrolides differ in their classification, 
belonging to category I (very high importance) and II (high importance), respectively [55]. 
Category I and II antimicrobials are the preferred treatment of serious infections in humans, with 
a category I antimicrobial having no or limited alternative antimicrobials available for treatment 
[55]. Phenicols and tetracyclines are both classified as category III (medium importance). 
Category IV antimicrobials, such as ionophores, are not used in human medicine. 
Label claims specific to one or more of the BRD bacterial agents exist for all 
antimicrobials licensed for treatment (Table 1.1). However, tulathromycin (i.e., Draxxin®) and 
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gamithromycin (i.e., Zactran®) have specific label claims for M. bovis in cattle along with the 
other three BRD bacterial agents (i.e., M. haemolytica, P. multocida, and H. somni) [56]. As 
BRD is a polymicrobial disease, M. bovis can be exposed to antimicrobials that are being 
administered to treat infections caused by other bacterial BRD pathogens. Given that no vaccines 
exist for M. bovis, antimicrobials remain the primary therapeutic option for prevention and 
treatment of infections. In instances of chronic M. bovis infections, these bacteria are often 














Class Health Canada Categorization 
WHO 
Classification Indication in Cattle†† 
Enrofloxacin 
(eg. Baytril® 100; 
DIN: 02249243) 
2004 Fluoroquinolone 




BRD (M. haemolytica and P. multocida) 
Tulathromycin 
(eg. Draxxin®; 
DIN: 02285452 ) 
2006 Macrolide II, high importance Critically Important 
BRD (M. haemolytica, P. multocida, H. 




2010 Macrolide II, high importance Critically Important 
BRD (M. haemolytica, P. multocida, H. 




1990 Macrolide II, high importance Critically Important 




2012 Macrolide II, high importance Critically Important 
BRD (M. haemolytica, P. multocida, and H. 
somni) 
Tylosin 
(eg. Tylan™ 200; 
DIN: 00103594 
1968 Macrolide II, high importance Critically Important 
Pneumonia (P. multocida and Actinomyces 
pyogenes), and contagious calf pneumonia 




1996 Phenicol III, medium importance Highly important 
BRD (M. haemolytica, P. multocida, H. 
somni), bovine interdigital phlegmon, and 
infectious keratoconjunctivitis 
Oxytetracycline 
(eg. Oxyvet® 200 
LA; DIN: 
02184575) 
1996 Tetracycline III, medium importance Highly important 
Bacterial pneumonia, black leg, calf 
diphtheria, calf scours, foot rot, joint ill, 
leptospirosis, mastitis, metritis, navel ill, 
pasteurellosis, and peritonitis. 
Chlortetracycline* 
(eg. Chlor 50; 
DIN: 00641804) 
1985 Tetracycline III, medium importance Highly important 
Bacterial diarrhea and foot rot 
*Administered orally. †Year to market for the drug indicated, based in their drug identification number (DIN) in the Health 





 One of the issues of AMR has to do with the limited development of new antimicrobials. 
Since the golden age of antimicrobial discovery from the 1950s to 1970s, more recent 
antimicrobial drug registrations are the result of structural modifications of previously 
discovered antimicrobials [58]. For instance, tildipirosin and tilmicosin are derivatives of tylosin 
[59] (Figure 1.2). It is estimated that it can cost in excess of 1.5 billion (US) dollars to develop 
and bring a new antimicrobial product to market [60]. In order to bring a product to market, it 
must undergo rigorous testing and be licensed for a specific use. This can be problematic for 
veterinary medicine, as it is cost prohibitive to test a new antimicrobial for safety in all livestock 
species prior to licensing. As a strategy to provide effective treatment of animals, extra-label 
drug use (ELDU) can be used at the discretion of the veterinarian with a valid veterinary-client-
patient relationship [61].  ELDU refers to the use of a drug in an animal that is not in accordance 
with the approved label, insert, or registration, as licensed by Health Canada [62]. 
 
Figure 1.2 Tylosin (TYLT), and its two derivatives tilmicosin (TIL) and tildipirosin (TIP) have a 








1.4.3.2 Mode of Action 
As M. bovis does not have a cell wall nor do they synthesize folate, it is intrinsically 
resistant to antimicrobials that target the cell wall (β-lactams) or folic acid synthesis 
(sulfonamides) [6,20]. Therefore, the antimicrobials that target M. bovis focus on protein 
synthesis and deoxyribonucleic (DNA) replication. Macrolides and florfenicol bind to the 50S 
ribosomal subunit; whereas tetracyclines bind to the 30S ribosomal subunit [29,63]. As these 
antimicrobials target parts of the small (30S) and large (50S) ribosomal subunits, they exert their 
effect by interfering with protein synthesis. The small ribosomal subunit normally binds mRNA 
and facilitates the interaction between mRNA and tRNA, whereas the large ribosomal subunit 
facilitates peptide bond formation as it contains the peptidyl transferase site [63]. Interference 
with protein synthesis prevents M. bovis growth, allowing the immune system to clear the 
infection. For this reason, antimicrobials that interfere with protein synthesis are considered 
mycoplasmostatic. Whereas, fluoroquinolones exert their effect on components of DNA 
replication, through interactions with DNA gyrase and topoisomerase IV [29], which leads to 
cell death and hence these antimicrobials are considered to be mycoplasmacidal. 
1.4.3.3 Resistance Mechanisms 
 Unlike other bacterial agents associated with BRD, antimicrobial resistance genes have 
not been identified in M. bovis. However, genes conferring antimicrobial resistance, such as 
tet(M) encoding for a ribosomal protection protein, have been found in Mycoplasma hominis 
[64], a mycoplasma associated with humans. Ribosomal protection proteins exert their effect by 
interfering with the binding of tetracyclines [65]. Therefore, while it is possible that M. bovis 
could have antimicrobial resistance genes, to date they have not been reported. However, even in 
the absence of resistance genes, reduced susceptibility of M. bovis to antimicrobials has been 
reported in Canada [10-13] and worldwide [14-22]. 
There are four resistance mechanisms employed by bacteria: altered cell wall or 
membrane permeability, antibiotic inactivation, use of alternate metabolic pathways, and target 
modification [66]. In addition to intrinsic antibiotic resistance, the main mechanism of 
antimicrobial resistance described for M. bovis is through target modification as a result of single 
nucleotide polymorphisms (SNPs) [4,67]. A SNP is a single nucleotide change at a given 




advantages such as resistance to antimicrobials. For the purposes of this thesis SNP is used 
interchangeably with single nucleotide variant (SNV). Mycoplasma spp. are believed to undergo 
a comparatively high rate of mutation, due to deficiencies in DNA repair mechanisms [31], and 
this is thought to be one of the reasons why mycoplasmas can rapidly become resistant to 
antimicrobials.  
Target modifications, such as SNPs in the 16S and 23S rRNA interfere with the binding 
of antimicrobials to these ribosomal components. Tetracycline antimicrobials interact with the 
16S rRNA at the Tet-1 binding site [68]. The Tet-1 biding site forms a clamp-like structure 
around the A-site for binding of tRNA and possesses two main domains. These domains consist 
of helix 34 (1054-1056 and 1196-1200; E. coli numbering) and the loop next to helix 31 (964-
967) [68]. Mutations at 965 (A965T) and 967 (A967T/C) in M. bovis increase resistance to 
tetracyclines [22,67-69]. Changes at position 1058 (G1058A/C) have also been shown to confer 
resistance to tetracyclines [22,68].  
Mutations that preclude the binding of macrolides to 23S rRNA have also been observed 
in M. bovis and other Mycoplasma spp. [67], with mutation hot spots occurring in domains II and 
V [69]. Increased resistance to different 50S subunit inhibitors (i.e., tilmicosin, lincomycin,  
tylosin) has also been observed through the accumulation of SNPs in domain II and V [67]. The 
main interaction within the ribosomal tunnel occurs at A2058 (domain V), with additional 
interactions occurring at G745, G748, or A752 (domain II) [59]. Methylation in G748 and 
A2058 have also been shown to be synergistic in reducing the susceptibility of M. bovis to 
tylosin [70]. High minimum inhibitory concentrations (MICs) to macrolides and florfenicols at 
position 534 has also been associated with increased resistance in M. bovis [67]. In general, 
single mutations appear to reduce susceptibility, but mutations in both copies of the rrl gene 
within 23S rRNA resulted in higher MICs (>128 µg/mL) to macrolides [71]. It has been shown 
that different sugar residues on a macrolide interact uniquely with the ribosome [71]. For 
example, in a static model, tulathromycin was too small to extend across the ribosome tunnel to 
interact with G748, unlike tylosin, tilmicosin, or tildipirosin [59]. Mutations in ribosomal 
proteins L4 and L22, encoded by rplD and rplV, have also been shown to impart macrolide 




these proteins have been reported for macrolide resistant M. bovis, their role in resistance 
remains elusive [20]. 
Genes that encode for proteins that make up DNA gyrase (gyrA and gyr B) and 
topoisomerase IV (parC and parE), known as the quinolone resistance determining regions 
(QRDR) have been observed to have non-synonymous mutations that confer resistance to 
fluroquinolones, such as enrofloxacin [73]. Amino acid substitutions have been observed in 
gyrA, gyrB, and parC [67,73,74] in M. bovis isolates with reduced susceptibility to 
fluoroquiniolones. A Ser83Phe mutations in gyrA has been observed in intermediate (0.5-
1µg/ml) and resistant (≥ 2 µg/mL) M. bovis isolates; whereas Asp84Asn in parC was observed in 
resistant isolates [73]. Similarly, mutations in gyrA (Ser83Phe), gyrB (Val320Ala), and parC 
(Ser80Ile) were reported to occur in isolates with fluoroquinolone MICs > 10 µg/mL [67]. At 
this point, no mutations that confer antimicrobial resistance have been identified in parE [67]. 
The trio of other bacterial species associated with BRD (M. haemolytica, P. multocida, 
and H. somni), have known genes and integrative conjunctive elements (ICE) associated with 
their resistance profiles [46]. ICE are associated with horizontal gene transfer, allowing for 
genome plasticity in both gram positive and gram negative bacteria. All ICE have three 
conserved modules involved in integration, excision, conjugation, and regulation [75]. However, 
the specific genes and mechanisms involved in these conserved modules can vary among ICE 
[75]. Two ICE have been detected in M. bovis PG45, ICEB-1 and ICEB-2 [76]. The majority of 
the differences between the primary reference genome of Hubei-1, a strain isolated in 2008 from 
a pneumonic calf in China [77], and PG45 is due to the absence of ICEB-1 which contains genes 
encoding hypothetical proteins and variable surface lipoproteins [77]. At present, it is unknown 
if this region has evolved to acquire antimicrobial genes as is the case with ICE in other BRD 
bacteria.  
1.4.4 Alternative and Preventative Strategies 
There are currently no effective commercialized vaccines for M. bovis [6,20], but 
vaccines do exist for other BRD agents, such as M. haemolytica. Vaccines for the other BRD 
bacterial and viral agents are routinely administered upon arrival at the feedlot. Vaccines are 
currently not a viable therapeutic alternative to antimicrobials for treating M. bovis, owing to its 




Furthermore, in order to develop a vaccine, tissue culture models need to be developed. 
However, the clinical presentation of M. bovis is difficult to replicate in the lab, due to 
confounding factors associated with the host’s immune system such as stress exposure, age, 
breed, and the polymicrobial and chronic nature of diseases associated with M. bovis. Thus, there 
are no suitable models that are representative of a natural M. bovis infection [78]. Therefore, the 
combination of varied immunogenic targets and the lack of a viable infection model has hindered 
the development of an effective vaccine against M. bovis.  
1.5 Mycoplasma bovis 
1.5.1 Genome 
Until 1975, M. bovis was misidentified as a subspecies of Mycoplasma agalactiae, which 
is the causative agent of contagious agalactiae [79]. M. bovis is very small bacterium (0.2-0.5 
µm), approximately 20% smaller than other bacterial species, such as Escherichia coli [80]. M. 
bovis is considered to be one of the smallest self -replicating organisms, with its economized 
genome bordering on containing the minimum number of genes to sustain bacterial life [1]. M. 
bovis has a circular genome, approximately 1 Mbp, with the first sequenced genome published in 
2011 [M. bovis PG45, 76]. The PG45 genome was derived from an isolate taken from a mastitic 
milk sample on a dairy farm in the United States in the 1960’s [41]. This isolate has 826 open 
reading frames with an 89% coding density, 61 of which are pseudogenes. The PG45 genome 
has a reduced guanosine/cytosine (G/C) content of 29.3%. However, the G/C content is not 
consistent among mycoplasmal genomes, with areas encoding for rRNA and tRNA having 
comparatively higher G/C content, likely due to the conserved nature of these genes in 
prokaryotes [31]. 
M. bovis has a reduced number of ribosomal RNA (rRNA) genes, with two rrn loci in the 
PG45 reference genome encoding for rRNA [76] compared to seven in E. coli K12 substrain 
MG1655 [81]. A rrn operon, which contains several rRNA genes under the control of a single 
promoter, is typically in a rrs-rrl-rrf configuration encoding for 16S, 23S, and 5S rRNA, 
respectively [82]. In M. bovis, the rrn loci consist of tandem rrs-rrl alleles, with rrf present at a 
distant site, as depicted in Figure 1.3. Having multiple copies of rRNA genes allows for 
redundancy in case of deleterious mutations. However, reduced copies of these genes results in 




antimicrobial susceptibility as mutations in rRNA are associated with reduced susceptibility to 




Figure 1.3 Mycoplasma bovis PG45 complete genome. rRNA genes are depicted in red. Graphic 
prepared using Geneious version 2020.0 [83]. 
 
A caveat to economization of the genome, is the absence of complete pathways involved 
in vital cellular mechanisms such as biosynthesis and DNA repair mechanisms; therefore, 




cell. Based on complete sequencing of the M. bovis genome, deficits in both of these 
mechanisms have been reported [77]. The primary mechanism of maintaining the integrity of 
DNA in Mycoplasma spp. is through nucleotide excision repair, as it was the only complete 
repair pathway identified based on the comparative analysis of nine Mycoplasma spp. [84]. 
A number of genes encoding products in various biosynthetic pathways are missing in M. 
bovis, such as genes involved in the tricarboxylic acid cycle [77]. Therefore, it relies on 
glycolysis to generate cellular energy (adenosine triphosphate, ATP). However, it uses glycerol, 
rather than glucose to synthesize ATP through glycolysis as the 6-phosphofructokinase gene 
encoding phosphofructokinase is absent [77]. Pyruvate can also be used to generate ATP, 
following transformation into acetate via acetyl-CoA [77]. Therefore, growth media can be 
further supplemented with sodium pyruvate to stimulate growth. Additionally, M. bovis is largely 
reliant on external sources of amino acids, purines, pyrimidines, and lipids [4]. In M. bovis, 
genes coding for the components of the tricarboxylic acid cycle and pentose phosphate pathways 
are also absent [77]. 
1.5.2 Pathogenicity and Virulence 
The ability of M. bovis to bind to epithelial cells is the first step in pathogenicity, where it 
adheres to epithelial cells through adhesins such as α-enolase and NADH oxidase that interact 
with plasminogen and fibronectin, respectively [85,86]. However, these proteins are not limited 
to a single function. In addition to being an adhesin, α-enolase is a glycolytic enzyme involved in 
the production of cellular energy [85] and NADH oxidase is involved in the production of 
hydrogen peroxide (H202) [86]. Once in contact with host cells, M. bovis produces various 
virulence factors, which aid in the establishment of chronic infections. Proteins such as α-enolase 
and NADH oxidase that exhibit multiple functions are common in M. bovis. For example, VSPs 
play a role in both adhesion and evasion of host immunity.  
Antigenic variations in M. bovis is generally associated VSPs [87]. There are 13 vsp 
genes at a single locus in M. bovis PG45: vspA, vspB, vspE, vspF, vspG, vspH, vspI, vspJ, vspK, 
vspL, vspM, vspN and vspO [87]. Tandem repeats within this region allows for rapid changes in 
their composition and expression, allowing VSPs to be both size and phase variable. Phase 
variation is due to an ON-OFF molecular switch, which is controlled within the operon and 




between vspA and vspO, results in vspC [88]. These mechanisms create antigenic heterogeneity 
so as to evade the host’s immune system. This rapid alteration of immunogens likely accounts 
for the failure to develop a suitable field vaccine against M. bovis, despite considerable effort by 
the mycoplasma community [78]. This trait could also account for the chronic nature of M. bovis 
infections. 
Slow growth rate, intracellular localization, modulation of the immune system, biofilm 
formation, and the production of secondary metabolites have all been investigated as factors that 
contribute to the chronic nature of M. bovis infections. Their slow growth rate enables them to 
gradually increase in the presence of the immune system, allowing time for the host to adapt 
rather than illicit an immediate immune response [80]. Studies have demonstrated the M. bovis is 
able to invade and replicate in primary embryonic calf turbinate cells [89] and bovine embryonic 
tracheal cells [90]. Additionally, M. bovis has been shown to enter various types of 
peripheripheral blood mononuclear cells (T cells, T helper cells, B cells, monocytes, γδ T cells, 
cytotoxic T cells, natural killer (NK) cells and dendritic cells) and erythrocytes [91]. In addition 
to invading erythrocytes, M. bovis possesses a gene encoding a hemolysin-related protein, which 
can lyse erythrocytes [77]. 
In addition to evading the immune system, intracellular localization also reduces 
exposure to antimicrobials. Furthermore, M. bovis is able to interact with immune cells such as 
neutrophils, macrophages and lymphocytes, and modulate their function. Specifically, delaying 
apoptosis in monocytes and alveolar macrophages [92], and further impeding the immune 
response by altering phagocytosis and antigen presentation [93]. Increases in anti-inflammatory 
cytokines, and a reduction of pro-inflammatory cytokines are additional mechanisms of immune 
modulation [94,95].  
M. bovis also forms biofilms, which form a barrier to protect M. bovis from immune 
defenses such as opsonization and complement mediated-lysis [93] and reduce the effectiveness 
of antimicrobials [26]. Biofilms not only contribute to the persistence of M. bovis, potentiating 
chronic infections, but also can damage host cells. As phagocytes are recruited to the biofilm, 
they release secondary metabolites such as lysozymes, reactive oxygen species (ROS) and 




extracellular cysteine proteases, which degrade extracellular matrix proteins directly (fibronectin 
and vitronectin) or indirectly (activating host metalloproteases) [77].  
Mycoplasmas are also capable of producing hydrogen peroxide [86]. However, levels of 
hydrogen peroxide were found to not be statistically different between M. bovis associated 
caseonecrotic bronchopneumonia, acute bronchopneumonia, chronic bronchopneumonia or non-
inflamed lung samples [96].  It has been suggested that hydrogen peroxide in combination with 
other ROS and RNS production results in the caseonecrotic lesions characteristic of M. bovis 
pneumonia [87,96]. Not only is hydrogen peroxide cytotoxic, but has been speculated that ROS 
produced by M. bovis modulates the immune response enabling persistent infections through 
promotion of a T helper 2 (Th2) versus a T helper 1 (Th1) response [96].  
1.5.3 Morphology and Growth Requirements 
On agar, M. bovis presents a characteristic “fried-egg” colony, with the white center 
being due to concentrated growth embedded in the agar (Figure 1.4). Mycoplasma spp. are 
fastidious with complicated nutritional requirements for growth in vitro. These characteristics, 
despite their significant impact on human and animal health, are largely why information on 
Mycoplasma spp. is limited. A pleuropneumonia like organism (PPLO) media base (broth or 
agar) is commonly used and is further supplemented with serum and yeast extract [97]. Serum is 
added, as a source of fatty acids, cholesterol and nucleotides [31]. Yeast extract is added as a 
source of micronutrients (vitamins and carbohydrates) and biosynthetic precursors (nucleosides, 







Figure 1.4 The “fried-egg” morphology of Mycoplasma bovis on solid media [99]. 
 
1.5.4 Diagnostics 
1.5.4.1 Conventional Clinical Methods 
Multiple diagnostic methods exist for M. bovis and each provide different information 
pertaining to clinical ailments or manifestations. The gold standard of bacteriology is still 
culturing, but given the fastidious nature of M. bovis this method is not ideal when results are 
required expeditiously. Additionally, culture-based methods are dependent on recovery of a 
viable organism and are sensitive to previous antimicrobial exposure [100]. Serological testing, 
such as enzyme-linked immunosorbent assay (ELISA) is a rapid method to detect M. bovis 
specific antibodies in serum [29], indicative of an immune response as a result of prior exposure 
to M. bovis. An additional advantage of ELISA over culturing is that it is not impacted by recent 
antimicrobial therapy [40]. However, it is not able to indicate whether the host is currently 
infected or shedding the bacterium in a transient manner. 
To expedite the identification process, DNA sequence based methods are widely used 
due to their sensitivity, specificity, and high-throughput capabilities [4]. DNA amplification can 
utilize the polymerase chain reaction (PCR) in both conventional and real-time platforms. As 
PCR amplifies a specific target sequence, only a small amount of purified DNA is required. 
Often a target of interest is the uvrC gene, encoding for excinuclease ABC subunit C [101], a 
protein involved in DNA excision and repair [35]. This gene is highly conserved among 
Mycoplasma spp. and has been shown to be an effective target to screen for M. bovis [102]. Not 




single or multiple targets. As cattle can be colonized by multiple Mycoplasma spp., multiplex 
PCR assays have been developed to identify multiple species in a single assay. For example, 
Parker et al. [103], developed a multiplex PCR that simultaneously targeted M. californicum, M. 
bovigenitalium, and M. bovis. 
As different diagnostic methods provide different information they can be combined to 
provide further insight into M. bovis infections. For instance, when M. bovis was confirmed to be 
in New Zealand’s cattle herd in 2017, a surveillance program to eradicate it from their national 
herd was implemented. This surveillance program utilizes two identification methods designed to 
address M. bovis infections at the individual and herd level, respectively. PCR is used to detect 
animals that are shedding M. bovis and an ELISA to detect animals that have been exposed to the 
organism [104]. All herds found to be positive are culled in an effort to remove the M. bovis 
reservoir from the island [105]. 
1.5.4.2 Whole Genome Sequencing 
Whole genome sequencing (WGS) is a version of high-throughput sequencing (HTS), 
where the input nucleic acid is DNA. In HTS, there are four general stages: data generation, 
primary analysis, secondary analysis, and tertiary analysis [106]. Data generation consists of 
bacterial isolation and nucleic acid extraction. The quality of sequencing information generated 
is highly dependent on the extraction method, yield, purity, and integrity of the DNA [106]. 
Following a quality control check of the extracted DNA, the next stages of data generation 
include library sequencing and computational analysis [106]. In the primary analysis, quality 
assurance and quality control procedures are performed on the raw read information [106]. 
Secondary analysis involves assembly of the raw reads, which can be done de novo or through 
alignment against a reference sequence, while the tertiary analysis is the interpretation of the 
sequence information [106]. 
HTS can be done utilizing next-generation sequencing (NGS) technologies. Regardless of 
the different procedures for DNA extraction, there are three main steps: lysis, precipitation, and 
purification. In the lysis step, cells are lysed chemically or mechanically and enzymes such as 
proteinase K and RNAse are added to digest contaminating proteins and RNA. Next, the DNA is 
precipitated and purified by separating out the DNA from contaminants via a solid (column-




purity, concentration, and integrity. Purity can be assessed quantitatively, using 
spectrophotometric (A260/A280) readings, or qualitatively, using agarose gel electrophoresis. 
Furthermore, concentration can be determined using fluorometric readings, such as Qubit 
(Thermo Fisher) and integrity can be assessed using gel electrophoresis. 
Built upon the technology used to sequence individual amplicons, some NGS 
methodologies rely on amplification. Amplification, and subsequent sequencing, allows for 
reconstruction of the sequence of interest multiple times over in a high-throughput manner [107]. 
When utilizing Illumina sequencing technologies, DNA is fragmented into 250-1000 bp and 
indexed to generate a genomic library for each sample [108]. The final pooled library is loaded 
onto the sequencer, where the adapter sequences bind to their complementary oligonucleotide in 
a flow cell [109]. DNA fragments are then clonally amplified through bridge amplification to 
generate clusters. The reverse template is removed, and the remaining forward strand is 
sequenced using fluorescently labelled nucleotides in a process commonly referred to as 
‘sequencing by synthesis’ to produce read 1. In paired-end sequencing, read 2 is generated in a 
similar manner by using the reverse strand as a template. Following completion of sequencing, 
samples can be separated based on their unique indices [109]. The cost of NGS has fallen rapidly 
and hence its use is growing in popularity for investigating antimicrobial resistance and in 
epidemiological studies [103,107,110,111]. Important for the context of this thesis, NGS can also 
be utilized for WGS [107]. 
1.5.5 Clinical Findings of Antimicrobial Resistance 
For antimicrobial stewardship, it is important to know the susceptibility of pathogens to 
specific antimicrobials, so that the correct antimicrobial can be administered. Global efforts to 
monitor changes to phenotypic and genotypic traits of M. bovis have been undertaken. As there 
is currently no established methodology for M. bovis AST, it is challenging to compare minimum 
inhibitory concentration (MIC) values among studies. However, two studies have looked at M. 
bovis isolates spanning three decades, allowing for comparison of isolates overtime. These two 
studies have been undertaken using field isolates from cattle in France [17] and Eastern Canada 
[13] using agar and broth dilution methods, respectively. The French isolates were from calves 
with BRD acquired through the national surveillance network of ruminant mycoplasmoses 




beef and dairy animals submitted to a clinical laboratory. In these studies, a general increase in 
the MIC for 50% of the isolates (MIC50) over three decades (1978 to 2012) was observed, 
indicating reduced antimicrobial susceptibility. The MIC50 increased for tulathromycin, 
tilmicosin, and tylosin [13,17], but remained constant at 128 µg/mL for gamithromycin and 
tildipirosin [17]. Fluoroquinolone resistance, specifically enrofloxacin, was consistently low 
(MIC50 = 0.25 µg/mL) across the three decades. Within the tetracyclines, the MIC50 for 
oxytetracycline and chlortetracycline in Canadian isolates increased by a single dilution from 2 
to 4 µg/mL; whereas, in France the MIC50 for oxytetracycline remained elevated at ≥ 32 µg/mL 
over the 30 year period. There was no change observed in the susceptibility to florfenicol over 
this time period. Overall, there has been a reduction in the susceptibility of M. bovis to 
macrolides, whereas the susceptibility to florfenicol, oxytetracycline, and chlortetracycline has 
remained largely unchanged. Fluoroquinolones remain the most effective antimicrobial, but MIC 
values have increased overtime [67]. 
 In general, these studies provide evidence that over time there has been a reduction in the 
number of suitable antimicrobials to treat M. bovis infections. This reduction in susceptibility 
could be due to increased antimicrobial use and thus exposure and selection for resistant strains. 
Antimicrobials administered to cattle could be effective against other BRD bacterial agents, but 
not against M. bovis. Therefore, it is possible that M. bovis still undergoes antimicrobial exposure 
and selection indirectly as antimicrobial treatment is primarily targeted at other BRD agents. 
Measuring AST is time consuming and expensive, making it desirable to have a genotypic 
method to select suitable antimicrobial therapies. Although this approach has been explored 
[22,67], assessment of causative versus predictive genotypes is still ongoing and requires 
concordance studies with paired phenotypic (AST) and genotypic (SNP) data. 
1.5.6 Antimicrobial Susceptibility 
Antimicrobial resistance of M. bovis is of global concern as it has been increasing 
[12,13,17,40]. Susceptibility of M. bovis to tetracyclines, macrolides, phenicols, and 
fluoroquinolones has been studied. A number of methods including E-test, agar dilution and 
broth dilution can be used to estimate antimicrobial susceptibility. Broth and agar dilutions are 
performed by doing 2-fold serial dilutions of an antimicrobial in broth or agar [112]; whereas the 




plastic strip [113]. Each method utilizes a standardized bacterial suspension when determining 
the MIC, which is defined as the minimum concentration of an antimicrobial that prevents 
visible growth of a microorganism [112]. When AST is done in broth for M. bovis, coloured 
indicators like alamarBlue (resazurin) [13,15,19,21,36,] or phenol red [16,18,114] can be used. 
AlamarBlue detects redox changes using resazurin [15] (Figure 1.5); whereas, phenol red detects 
a reduction in pH [115]. 
 
 
Figure 1.5 Sensititre plate with alamarBlue following 48 h incubation. The Mycoplasma bovis 
isolate was derived from lung tissue collected during a postmortem examination. Minimum 
inhibitory concentrations are indicated in black text with antimicrobials coded by class using 
coloured circles: white, fluoroquinolone; orange, macrolide; red, phenicol; green, tetracycline; 
and blue, β-lactam. A1-A11, enrofloxacin 0.12-128 µg/mL; B1-B11, tildipirosin 0.12-128 
µg/mL; C1-C11, gamithromycin 0.25-256 µg/mL; D1-D11, tulathromycin, 0.25-256 µg/mL; E1-
E11, florfenicol 0.25-256 µg/mL; F1-F10, oxytetracycline 0.5-256 µg/mL; G1-G9, 
chlortetracycline 1-256 µg/mL; H1-H9, tilmicosin 1-256 µg/mL; 12A-12H, tylosin tartrate 1-128 
µg/mL; 11F-11H, penicillin 2-8 µg/mL; 10G/10H, positive control (+, no antimicrobial). Growth 
assessed based on a blue-to-pink colour change. Colour change due to interference between 




One of the greatest limitations of AST for M. bovis is that there are no standardized 
breakpoints or protocols from international organizations such as Clinical and Laboratory 
Standards Institute (CLSI) or European Committee on Antimicrobial Susceptibility Testing 
(EUCAST). Therefore, this makes comparisons of absolute MIC determinations from different 
publications challenging, if not impossible. Antimicrobial sensitivity testing assesses in vitro 
susceptibility to antimicrobials, but does not necessarily reflect in vivo sensitivity [21]. Clinical 
breakpoints do exist for human mycoplasmas, such as M. hominis and Mycoplasma pneumoniae 
[28] and for the BRD pathogens M. haemolytica, P. multocida, and H. somni [116]. Clinical 
breakpoints are used to establish ranges to determine whether a particular bacterial isolate is 
sensitive, intermediate or resistant to a specific antimicrobial [117]. These classifications are 
used to guide therapeutic choices, as they are associated with successful, uncertain, or failed 
antimicrobial therapy [117]. 
  Clinical breakpoints are used to predict the probability of treatment success [112]. These 
breakpoints are specific to a susceptibility protocol, and take into account the pharmacokinetic 
and pharmacodynamic properties of a specific antimicrobial. Pharmacokinetics relates to the 
absorption, distribution, metabolism, and excretion (ADME) of a drug within an individual 
[118,119]. Pharmacodynamics focuses on how a drug works based on its unbound drug 
concentration and antimicrobial effect [119]. Therefore, without established clinical breakpoints 
for M. bovis, it is not possible to correlate in vitro MIC to clinical efficacy of an antimicrobial in 
vivo. However, MICs for human Mycoplasma spp. [28] and other respiratory pathogens in cattle 
[116] have been used as a guide for interpretation of resistance in M. bovis [11,12,15,16,29]. 
1.5.7 Epidemiological cut-off value (ECOFF) 
The ECOFF is an alternative method to describe isolates in a population on the basis of 
antimicrobial susceptibility and was established in an effort to detect biological phenotypic 
resistance [117], as opposed to success of treatment indicated by clinical breakpoints [112]. In an 
effort to improve the basis of comparison for genotype-phenotype concordance studies, the use 
of an ECOFF as opposed to a breakpoint has been proposed [110]. An ECOFF is defined as the 
highest MIC where acquired resistance mechanisms are not phenotypically detectable [110], and 
is determined based on the distribution of MIC values for a specific antimicrobial in a given 




intermediate, or resistant to a specific antimicrobial using clinical breakpoints, isolates are 
classified as wildtype or non-wild type. Wildtype (WT) organisms do not have any known 
phenotypically detectable resistance; whereas a non-wildtype (NWT) organism exhibits 
phenotypic resistance. Additionally, WT organisms do not exhibit resistance regardless of year, 
geographic or anatomical location of sampling [110]. An ECOFF can provide complementary 
information to clinical breakpoints, but clinical breakpoints do not differentiate WT from NWT 
organisms. For each ECOFF group, isolates can be clinically categorized as susceptible, 
intermediate or resistant phenotypes. 
1.5.8 Strain Type Differentiation 
To resolve differences in bacterial isolates, bacteria can be categorized based on a set of 
characteristics. This can be done using phenotyping, genotyping, or a combination of both . 
Categorizing isolates based on these characteristics is known as typing. The ability to 
differentiate isolates is the cornerstone of epidemiological surveillance [120]. There have been 
multiple strategies employed to genotype M. bovis, including restriction fragment length 
polymorphism (RFLP), pulsed field gel electrophoresis (PFGE), multilocus sequence typing 
(MLST) and SNP analysis [121]. Both RFLP and PFGE are examples of fingerprinting methods 
that use different sizes of genomic fragments to infer sequence differences. Both MLST and SNP 
are sequencing based methods [121] and as technological advances have been made these 
procedures have been more widely adopted. Sequence methods employed in this thesis include in 
silico MLST, core genome MLST (cgMLST), core genome single nucleotide variant (cgSNV) 
and whole genome SNV (wgSNV) analysis. 
MLST is traditionally done using PCR, targeting a small number of housekeeping genes 
with specific primer pairs, followed by sequencing the individual amplicons [97]. However, 
MLST can also be done in silico from WGS information. There are two published MLST 
schemes for M. bovis, both consisting of seven housekeeping genes [97,122]. The scheme 
originally proposed by Register et al. [97] included alcohol dehydrogenase-1 (adh-1), glutamate 
tRNA ligase (gltX), glycerol-3-phosphate dehydrogenase (gpsA), DNA gyrase subunit B (gyrB), 
phosphate acetyltransferase-2 (pta2), thymidine kinase (tdk), and transketolase (tkt). The scheme 
by Rosales et al. [122] also used tdk, in addition to the chromosomal replication initiator protein 




elongation factor Tu1 (tufa), ATP synthase subunit alpha (atpA), and RNA polymerase sigma 
factor (rpoD). In some M. bovis isolates, the adh-1 gene has not been detected using the Register 
et al. [97] scheme, making these isolates untypeable. However, the scheme has recently been 
revised, by replacing adh-1 with dnaA [123]. Both of the schemes are curated and hosted on 
PubMLST (https://pubmlst.org/mbovis/). 
Core genome MLST is built upon the same molecular principals as MLST, but instead of 
looking at a few genes, cgMLST uses hundreds of genes. This allows cgMLST to discriminate 
genotypic differences using a larger portion of the genome. cgMLST has been utilized for 
epidemiological studies for other veterinary Mycoplasma spp. [124,125], as well as in a recent 
epidemiological investigation of M. bovis associated with mastitis in two dairy herds in Finland 
[111].  
cgSNV analysis involves determining which genomic regions are similar in all isolates of 
interest, then looking for SNPs that occur in these common to “core” areas; whereas wgSNV 
queries across the entire genome. A SNP analysis approach has been performed previously using 
75 Australian M. bovis isolates from clinical and non-clinical dairy cattle spanning 2006 to 2015, 
and found these to be genetically similar with a maximum of 50 SNPs observed among isolates 
[103]. 
In silico MLST, cgMLST, cgSNV and wgSNV analysis are capable of different levels of 
resolution, and are compatible with WGS information. The trade-off for resolution is in the 
complexity of analysis for each typing approach. In silico MLST, cgMLST, cgSNV and wgSNV 
analysis have increasing levels of resolution as well as increasing analytical complexity and 
computational requirements. One of the benefits of a genomics based approach utilizing WGS is 
that as new questions arise, the genomic information can be interrogated at a later date without 
having to perform additional lab processes. The phylogenetic relationship of isolates constructed 
using the different typing method can allow the relationship between the isolates, and the 
possible evolutionary history to be determined. This can allow for phenotypic prediction, which 




1.5.9 Surveillance Programs 
1.5.9.1 Canada 
The Canadian Integrated Program for Antimicrobial Resistance Surveillance (CIPARS) 
was started in 2002 and is a One Health initiative coordinated by the PHAC [126]. The program 
assesses trends in AMU and AMR concerning both humans and animals [127]. One Health is a 
multimodal approach that considers human health, animal health, and the environment. One 
Health follows the tenet that these entities do not act as discrete units, but rather act in concert 
with one another. Therefore, the most effective way to address AMR requires collaboration of 
government, private industry, and academic stakeholders within these entities. The focus of 
CIPARS is primarily on food-borne pathogens such as Salmonella, Campylobacter, and E.coli. 
Recently, M. haemolytica a member of the bacterial complex associated with BRD, is a bacteria 
of interest for CIPARS. 
1.5.9.2 Europe 
In Europe, there is the MycoPath pan-European antimicrobial susceptibility monitoring 
program that was developed specifically to focus on mycoplasmal species in agriculture  [114]. 
Of particular interest to the program is M. hyopneumonia in pigs and M. bovis in cattle [21]. The 
isolates collected in the program are from clinical cases in livestock that have not been recently 
exposed to antimicrobials [114]. Through continually monitoring the susceptibility of isolates, 
the aim of the program is to monitor resistance and ensure that effective therapies are 
administered. 
1.5.9.3 New Zealand 
In 2017, M. bovis was found in cattle at a dairy farm in New Zealand. This led to a trace 
back program to determine the source of M. bovis, and ultimately the decision in May 2018, to 
attempt to eradicate M. bovis from New Zealand [128].  The decision to eradicate was due to the 
welfare and economic impact of clinical conditions (pneumonia, arthritis, mastitis, otitis media, 
conjunctivitis), the additional cost of production due to treatment and disease management, and 
its poor response to available therapies [128]. As the number of herds impacted were limited, 
eradication through depopulation was chosen to limit the impact of M. bovis on the dairy and 
beef industries in New Zealand. It is estimated that full eradication will take 10 years and cost 





1. Describe the usage of antimicrobials and the presence of antimicrobial resistant isolates 
in western Canadian feedlot cattle mortalities due to Mycoplasma bovis. 
2. Investigate the genotypic basis for macrolide resistance in Mycoplasma bovis isolates 
using whole-genome sequencing to assess single nucleotide polymorphisms in the 23S 
rRNA gene alleles and ribosomal proteins L4 and L22. 
3. Assess the concordance of four genotyping methods to Mycoplasma bovis isolates 
derived from western Canadian feedlot cattle and the ability of each method to resolve 
phenotypic differences based on genotype. 
The primary objectives of this thesis were to describe the usage of antimicrobials and the 
presence of AMR in relation to M. bovis related disease, investigate the genotypic basis for 
macrolide resistance, and assess the suitability of four different in silico genotyping methods for 
the phylogenetic analyses of M. bovis. In order to achieve these objectives, a series of three 
related and interdependent studies were conducted and described in Chapters 2, 3 and 4 of this 
thesis. 
In general, AMU and AMR are a global concern. In western Canadian feedlot cattle, 
antimicrobials are central to the prevention and treatment of M. bovis infections. Chapter 2 
describes the AMU and AMR of M. bovis isolates of western Canadian feedlot cattle. Although 
Chapter 2 describes AMR and AMU based on data obtained from western Canadian feedlot 
cattle, this chapter was not intended to be representative of all western Canadian feedlots but 
rather provide context on AMR and AMU in feedlots and the background of the cattle and 
isolates represented in this thesis.  
AST of M. bovis traditionally requires culture-based methods which are time consuming 
and not amenable to rapid and routine assessment, unlike molecular methods which directly 
query the genome. In order to assess the relationship between genotype and phenotype for AMR, 
M. bovis isolates underwent both WGS and AST. Due to the elevated AMR and reliance on 
macrolides for treatment and prevention of M. bovis disease in feedlots, the study in Chapter 3 
focuses on macrolides to investigate the relationship between genotype (SNPs in genes 





 Throughout this thesis, isolates were derived from different anatomical locations 
(nasopharynx, lung, joint) of cattle with varying health status (healthy, d iseased, dead) in 
different feedlots over a 12-year period (2006 - 2018). As the ability to differentiate bacterial 
isolates is the cornerstone of epidemiological surveillance, the study outlined in Chapter 4 
utilizes four in silico genotyping methods (MLST, cgMLST, cgSNV, wgSNV) to assess the 
phylogenetic relationship of M. bovis isolates derived from western Canadian feedlot cattle and 
the ability to resolve phenotypic differences based on genotype. Lastly, Chapter 5 provides a 



















2 ANTIMICROBIAL USE AND THE SUSCEPTIBILITY OF MYCOPLASMA BOVIS 

























 Mycoplasma bovis has significant animal welfare and economic concerns given its 
association with BRD and CPPS in feedlot cattle. Antimicrobials are currently the only 
therapeutic option for treatment and control of M. bovis, making surveilling their administration 
and susceptibility crucial to their utility and judicious use. M. bovis isolates (n = 119) were 
cultured from the nasopharynx, lung, and/or joint of 74 western Canadian feedlot cattle that 
succumbed to M. bovis related disease over five production years (2014-2018). AMU was 
determined from feedlot treatment records and 93.2% of cattle received an antimicrobial 
metaphylactically upon arrival at the feedlot. An average of three antimicrobial classes was 
administered to an individual animal with more cattle having received additional antimicrobial 
classes later in the feeding period (> 60 DOF). Antimicrobial susceptibility was assessed for nine 
antimicrobials commonly administered to feedlot cattle using a microbroth dilution assay.  Most 
isolates (> 92 %) were resistant to each of the five macrolides tested and 50.4% were resistant to 
enrofloxacin. The greatest susceptibility (89.9%) was observed to florfenicol, despite 78.4% of 
animals having been administered it. Overall, AMR was present in western Canadian M. bovis 
isolates.  
2.2 Introduction 
 M. bovis infections pose both economic and animal welfare concerns for Canadian 
feedlot operators, through its association with BRD and CPPS in cattle [2,3]. BRD typically 
occurs one to two weeks after arrival at the feedlot and is associated with multiple bacterial and 
viral etiological agents [32]. Other bacterial species associated with BRD include M. 
haemolytica, P. multocida, and H. somni [9]. Unlike BRD, CPPS is attributed to chronic M. 
bovis infections [49]. Economic losses occur due to reduced weight gain, increased associated 
treatment costs, and death [6,7]. 
Typically, most AMU in feedlot cattle is targeted towards BRD, but the role of M. bovis 
in this condition remains nebulous [3,6,45]. More frequently, AMU is more specifically directed 
at M. bovis for chronic pneumonia and CPPS, where clinical failure is common [6]. Prolonged 
antimicrobial therapy against these chronic infections selects for antimicrobial resistance in other 




Antimicrobials exert bacteriostatic and bactericidal effects through various mechanisms, 
such as interfering with cell wall, DNA, and protein synthesis. As M. bovis does not have a cell 
wall nor does it synthesize folic acid, it is intrinsically resistant to β-lactams and sulfonamides, 
respectively [6]. Therefore, antimicrobials used to treatment mycoplasmosis target DNA (i.e., 
fluoroquinonlones) and protein synthesis (i,e., macrolides, tetracyclines, and phenicols) [29,63]. 
Over time, M. bovis has tended to exhibit reduced susceptibility to these antimicrobials 
[13,15,17,20,22]. This is problematic as there are currently no effective vaccines for M. bovis 
[6,20], and as a result, antimicrobials remain the primary tool to control mycoplasmosis. Feedlots 
generally administer in-feed antimicrobials for the prevention and control of liver abscesses; 
whereas, individual parenteral metaphylaxis of antimicrobials is more typical for the control of 
BRD [44].  
Not only do antimicrobials have different modes of action, but they also differ in their 
utility to combat bacterial infections in humans. The classes of antimicrobials commonly used in 
western Canadian feedlot cattle to treat BRD include fluoroquinolones, macrolides, phenicols 
and tetracyclines [11,44]. Health Canada has classified antimicrobials based on their importance 
in human medicine and availability of alternative therapies [55]. Category I antimicrobials, 
including fluroquinolones such as enrofloxacin, are the preferred treatment of serious infections 
in humans for which there are no or limited alternatives [55]. Macrolides are a category II 
antimicrobial (high importance); whereas, phenicols and tetracyclines are both classified as 
category III (medium importance). A broader understanding of the sensitivity of M. bovis to 
these antimicrobials may enable veterinarians to select effective antimicrobial therapies without 
relying on category I or II antimicrobials. The objective of this study was to describe 
antimicrobial use and the subsequent antimicrobial susceptibility of M. bovis isolates derived 
from the nasopharynx, lung and joint in cattle. However, it should be noted that this chapter was 
not intended as a survey of AMU and AMR for all western Canadian feedlot cattle, but rather to 
provide general context and background for the cattle and M. bovis isolates used and discussed 




2.3 Materials and Methods 
2.3.1 Sampling 
M. bovis isolates (n = 119) were sampled from the nasopharynx, lung, and/or joint of 74 
feedlot cattle, spanning 5 production years (2014 - 2018) as described by Jelinski et al. [12]. 
Cattle were sampled from 10 feedlots. All samples were taken postmortem from cattle with 
pathological lesions consistent with BRD, chronic pneumonia, or CPPS. Production years were 
used to define the sampling cohort, as cattle often enter the feedlot in the fall and remain there 
until the following calendar year. Thus, the 2018 production year included samples obtained 
between November 1, 2018, and June 30, 2019. 
2.3.2 Compilation of Antimicrobial Use 
Feedlot treatment records were used to compile a history of antimicrobial treatments and 
included the antimicrobial, date of treatment and number of treatments. These treatment histories 
were compiled in spreadsheet format (Microsoft Excel, Microsoft Office, v. 15, Microsoft 
Corporation, Redmond, WA, USA). Although administration of antimicrobials in feed was not 
recorded for each animal, chlorotetracycline is frequently included in diet for 20-40 d post arrival 
to prevent BRD, and tylosin is administered for the remainder of the feeding period to reduce the 
incidence of liver abscesses [11]. 
Metaphylactic administration of antimicrobials was classified as those that were 
administered upon arrival at the feedlot. The active ingredient of each antimicrobial was 
determined by searching the product name in the Canadian edition of the Compendium of 
Veterinary Products [56]. Antimicrobials administered were then grouped into their respective 
classes based on active ingredients. Active ingredients were classified as follows (active 
ingredient, class): enrofloxacin, fluoroquinolone (FQ); ceftiofur, cephalosporin (CEPH); 
tulathromycin/tilmicosin, macrolide (MAC); oxytetracycline, tetracycline (TET); florfenicol, 
phenicol (PHEN); trimethoprim and sulfadoxine, trimethoprim-sulfonamides (TMS); and 
sulfanilamide/sulfathiazole/sulfamethazine, sulfonamide (SULF). 
2.3.3 Culture 
M. bovis was isolated from deep nasopharyngeal swabs and swabs from lung and joint 
tissue as described by Jelinski et al. [12]. Samples were cultured using pleuropneumonia-like 




supplemented with 10 g/L yeast extract (BD Diagnostic Systems, Fisher Scientific, Waltham, 
MA, USA), and 20% horse serum (Invitrogen, Fisher Scientific) [12,97]. Where specified, the 
media was supplemented with 0.05% thallium (I) acetate, 500 U/mL penicillin G, and/or 0.5% 
sodium pyruvate (Sigma-Aldrich, St. Louis, MO, USA). 
Cultures derived from samples were filtered through 0.45 and 0.20 µm filters (Basix, 
VWR International, Radnor, PA, USA), and were used to inoculate PPLO broth with 0.05% 
thallium (I) acetate, 500 U/mL penicillin G, and 0.5% sodium pyruvate, and grown in a 5% CO2 
atmosphere with 75% humidity at 37 °C. Cultures with visible growth were subcultured onto 
PPLO agar and incubated for 3-6 days. A single colony with characteristic “fried-egg” 
morphology was subcultured onto PPLO agar, and incubated for 72 h. Up to three individual 
colonies per sample were used to inoculate separate aliquots of PPLO broth. After 48 h, each 
culture was transferred to PPLO with 20% glycerol, and stored at –80 °C. A single stock culture 
was selected and used to inoculate PPLO to grow cells for antimicrobial susceptibility testing 
and DNA extraction. 
2.3.4 Identification 
M. bovis isolates were grown in PPLO media for 48 h and genomic DNA was extracted 
using the GenElute Bacterial Genomic DNA Kit (Sigma-Aldrich, St. Louis, MO, USA) as per 
manufacturer’s instructions with the exception that the final elution buffer was replaced with 10 
mM Tris (pH 8.5). Extracted genomic DNA was assessed for quality using gel electrophoresis 
and quantified fluorometrically using a Qubit analyzer (Thermo Fisher Scientific, Waltham, MA, 
USA). Cultures were confirmed as M. bovis, based on the presence of the uvrC gene [35] and 
sequencing of the 16S rRNA gene [129]. The 16S rRNA amplicon was purified using a 
QIAquick PCR kit (Qiagen, Nevlo, Netherlands) and Sanger sequencing at Macrogen (Seoul, 
South Korea). Forward and reverse sequences were assembled and edited using the Staden 
Package (version 1.6-r, http://staden.sourceforge.net/). The resulting sequences were compared 
to the National Center for Biotechnology Information (NCBI) nonredundant nucleotide database 
(nr) using BLASTn. 
2.3.5 Antimicrobial Susceptibility Testing (AST) 
AST was determined using a microdilution assay, in a customized Sensititre™ (Trek 




against BRD in North American feedlots [12]. AlamarBlue (ThermoFisher Scientific, 
DAL1100), a color redox indicator was used to assess growth in each well based on a blue to 
pink color transition. 
The AST procedure began by inoculating an M. bovis isolate previously stored at –80 °C 
in 20% glycerol into PPLO broth with 0.5% pyruvate and incubating for 72 h at 5% CO2 with 
75% humidity at 37 °C. M. bovis isolates were subcultured in PPLO for 24 h. Following 
incubation, the optical density (OD) at 450 nm was determined using a NanoDrop One 
Spectrophotometer (Fisher Scientific, Waltham, MA, USA) and the culture adjusted to an OD450 
= 0.1. The adjusted culture was diluted up to 100X, and 120 µL of the diluted culture was 
inoculated into 6 mL of PPLO in 2X AlamarBlue. Each well of a Sensititre™ plate was then 
inoculated (50 µL) into wells containing 50 µL of media with the appropriate concentration of 
each antimicrobial within a dilution series so as to achieve 1 x 103 to 5 × 105 CFU/mL in each 
well. Plates were sealed with a CO2 permeable film, and incubated for 48–72 h. Minimum 
inhibitory concentrations (MICs) were determined by visual assessment of growth in plates after 
48 to 72 h incubation based on a blue to pink colour change. Mycoplasma bovis ATCC® 
25523™ was included as a positive control. Susceptibility of the isolates to penicillin was also 
used as a control, as all M. bovis isolates should be intrinsically resistant to this antimicrobial. 
2.3.6 Clinical breakpoints 
As there are no established antimicrobial breakpoints for M. bovis, breakpoints were 
extrapolated from other members of the bacterial BRD complex (i.e., M. haemolytica, P. 
multocida, H. somni) and human Mycoplasma spp., as described by Jelinski et al. [12]. The 
resistance breakpoints used were ≥ 0.50 µg/mL for enrofloxacin; ≥ 4 µg/mL for florfenicol, 
oxytetracycline, and chlortetracycline, ≥8 µg/mL for tildipirosin, gamithromycin, tilmicosin, 
tylosin; and ≥32 µg/mL for tulathromycin. 
2.4 Results 
2.4.1 Cattle and Mycoplasma bovis isolation 
There were 119 isolates cultured from the nasopharynx (n = 12), lung (n = 66) and joint 
(n = 41) of 74 cattle at the time of postmortem examination (Table 2.1). Over half of the cattle (n 
= 42) came from a single feedlot (2016-2018), representing 62.2% of all isolates (n = 74). The 




isolates. There were 33 cattle that had a single isolate from the nasopharynx (n = 2), lung (n = 
25) or joint (n = 6), 37 had isolates from two anatomical locations (6 nasopharynx/lung pairs, 31 
lung/joint pairs) and 4 had isolates from all three anatomical locations. Nasopharynx samples 
were only collected in 2018; whereas lung and joint samples were collected across all years. 
 




2014 2015 2016 2017 2018 Total 
Nasopharynx     12 (10.1) 12 (10.1) 
Lung 7 (5.9) 10 (8.4) 16 (13.4) 16 (13.4) 17 (14.3) 66 (55.5) 
Joint 2 (1.7) 2 (1.7) 14 (11.8) 17 (14.3) 6 (5.0) 41 (34.5) 
Total 9 (7.6) 12 (10.1) 30 (25.2) 33 (27.7) 35 (29.4) 119 (100) 
 
2.4.2 Antimicrobial use 
Treatment records and AST results were compiled for 74 cattle from ten feedlots over 
five production years. Most (93.2%) cattle received metaphylaxis with 94.2% of this being 
tulathromycin (Draxxin®) (Table 2.2). 
 
Table 2.2 Antimicrobials administered to feedlot cattle upon arrival at the feedlot across five 
production years (n = 74). The number of cattle (%) that received each antimicrobial is indicated. 
Antimicrobial 
Production Year 
2014 2015 2016 2017 2018 Total 
Tulathromycin 4 (5.4) 9 (12.2) 16 (21.6) 17 (23.0) 19 (25.7) 65 (87.8) 
Oxytetracycline 1 (1.4) 2 (2.7)    3 (4.1) 
Tilmicosin    1 (1.4)  1 (1.4) 
None 3 (4.1)   2 (2.7)  5 (6.8) 





An average of three classes of antimicrobials were administered to cattle. This was 
consistent over the 5 sampling years, with the exception of 2015 where an average of four 
classes were administered. Overall, 66.2% of cattle received ≤ 3 classes of antimicrobials (Table 
2.3). The number of antimicrobials administered ranged from one to six, with 9.5% receiving 5 
or 6 different classes. At the time of death, cattle had spent from 9-217 DOF with 81.1% being ≤ 
60 DOF (Table 2.3). Of the cattle that received five or six classes, 57.1% were > 60 DOF at the 





Table 2.3 The number of feedlot cattle (n = 74) administered different antimicrobial classes by production year (2014 to 2018) 
and days on feed at the time of death. 




cattle (%)  1 2 3 4 5 6 
Production 
Year 
        
2014 2 2 2 2   3 8 (10.8) 
2015 1 1  3 4 2 4 11 (14.9) 
2016 5 2 5 3 1  3 16 (21.6) 
2017  7 11 2   3 20 (27.0) 
2018 1 2 8 8   3 19 (25.7) 
Days on Feed         
0-14 2      1 2 (2.7) 
15-30 3 4 6 2 1  3 16 (21.6) 
31-60 3 10 18 9 2  3 42 (56.8) 
>60 1  2 7 2 2 4 14 (18.9) 
Total 9 (12.2) 14 (18.9) 26 (35.1) 18 (24.3) 5 (6.8) 2 (1.7) 3 74 (100) 
*Antimicrobial classes assessed : FQ - Fluoroquinolone, CEPH - cephalosporin, MAC - macrolide, TET - tetracycline, PHEN - 
phenicol, TMS - trimethoprim-sulfonamides, and SULF – sulfonamide. † Average number of classes administered is rounded 




Of the seven possible classes of antimicrobials administered (Table 2.4), macrolides were 
administered to 93.2% (n = 69) of the cattle, primarily for metaphylaxis. Phenicols, 
fluoroquinolones, and tetracyclines were administered to 78.4 (n = 58), 67.6 (n = 50), and 18.9 % 
(n = 14) of cattle, respectively. Cephalosporins and trimethoprim-sulfonamides, were 
administered to 36.5 (n = 27) and 8.1 % (n = 6) of animals, respectively. 
 
Table 2.4 Use of antimicrobials in relation to the number of days on feed (DOF) at the time of 
death. Usage is shown as a percentage and absolute number (n) of feedlot cattle treated with each 
antimicrobial class for each cohort (DOF). 
DOF 
% (n) of 
Animals  
Antimicrobial Classes 






















































































FQ - Fluoroquinolone, CEPH - cephalosporin, MAC - macrolide, TET - tetracycline, PHEN - phenicol, TMS - 
trimethoprim-sulfonamides, and SULF – sulfonamides. 
2.4.3 Antimicrobial susceptibility  
Most (92.4 %; n = 110) isolates were resistant to all five macrolides tested with a MIC50 
≥ 128 µg/mL across all macrolide and approximately half (50.4 %) of all isolates were resistant 
to enrofloxacin (Table 2.5). Within the tetracycline class the proportion of resistant isolates 
ranged from 37.8 to 76.5% for oxytetracycline and chlortetracycline, respectively. Only 10.1% 





Table 2.5 Antibiotic susceptibility of Mycoplasma bovis isolates (n = 119) recovered from cattle (n = 74) between 2014 and 
2018. The dark vertical lines denote the resistance breakpoint, whereas the shaded cells are antimicrobial concentrations that 
were not tested. 





Tulathromycin Macrolide  6   1  2  1 3 20 86 92.4 0.25 256 256 
Gamithromycin Macrolide     1 2 2 1   3 110 97.5 2-128 256 256 
Tilmicosin Macrolide            119 100 256 256 256 
Tildipirosin Macrolide        1 1 3 114  100 16-128 128 128 
Tylosin Macrolide      2 1 2 5 4 105  98.3 4-128 128 128 
Enrofloxacin Fluoroquinolone 47 12   20 27 11 2     50.4 2-16 2 8 
Florfenicol   Phenicol  2 16 45 44 11 1      10.1 0.25 1 2 
Oxytetracycline Tetracycline   2 26 45 36 9 1     37.8 0.5-8 2 4 
Chlortetracycline Tetracycline    3 25 36 30 22 3    76.5 1-32 4 16 






2.5 Discussion and Conclusion 
 Antimicrobials are used extensively for the prevention and treatment of M. bovis 
infections in feedlot cattle in western Canada, given the absence of alternatives such as vaccines. 
From the 74 feedlot cattle sampled from 2014 to 2018, on average each animal was administered 
3 different antimicrobial classes and 93.2% of cattle were administered an antimicrobial 
metaphylactically upon arrival at the feedlot. Of the 119 M. bovis isolates recovered, AMR was 
present in >50% of isolates for 7 of the 9 antimicrobials assessed. However, 55.4 % of cattle (n = 
41) contributed more than one isolate, so these are not independent observations. These findings 
highlight the ubiquitous use of antimicrobials in western Canada and the elevated level of 
resistance present in M. bovis infected feedlot cattle. 
Over the five production years, M. bovis isolates exhibited resistance to an average of 
three antimicrobial classes, one more than that observed by Anholt et al. [11] for M. bovis 
isolates predominately collected from cattle that had died of BRD (528 of 618 animals) in 2014 
and 2015 in southern Alberta. This discrepancy could be due to the timing of sampling as cattle 
in their study were predominately sampled earlier in the feeding period (0-30 DOF) and included 
morbid cases; whereas, 75.7% of cattle in the current study were sampled at > 30 DOF during 
postmortem examination.  
The percentage of resistant isolates in this study overestimates the level of AMR in the 
general M. bovis population in western Canada, as all isolates were obtained from dead cattle 
that had received multiple antimicrobial treatments. As approximately half of the isolates were 
derived from lung/joint pairs from a single animal, with a third of all isolates derived from the 
joints, the sample set was largely comprised of isolates derived from animals chronically infected 
with M. bovis. Furthermore, overestimation could be due to culturing more than one isolate from 
an individual animal, which occurred in 55.4 % of cattle (n = 41). As death attributed to chronic 
M. bovis infections are difficult to treat [6], it is no surprise that a greater number of 
antimicrobial classes were administered to cattle later in the feeding period in an effort to control 
mycoplasmosis.  
Consistent with other reports, macrolides were the most common antimicrobial class 
administered upon arrival [11,44]. Nearly all cattle received metaphylaxis, with macrolides 





being treated, but only 10.1% of isolates exhibited resistance. The minimal resistance to 
florfenicol in M. bovis is encouraging since it is a lower category III antimicrobial and could 
serve as an alternative to category II macrolides. In a 2007 field trial in Alberta, calves treated 
with florfenicol and flunixin meglumine for undifferentiated fever (UF) had a significantly lower 
mortality rate than those that were treated with a macrolide or cephalosporin [130]. The fact that 
the frequent use of florfenicol in the current study did not promote resistance could be related to 
the timing of administration where florfenicol administration increased later in the feeding 
period. As chronic M. bovis infections are associated with caseonecrotic pneumonia and arthritis, 
reduced perfusion of the infection site could render the treatment ineffective even if M. bovis was 
susceptible. Additionally, the formation of biofilms could further limit the effectiveness of 
antimicrobials by decreasing access. However, an elevated level of florfenicol resistance (71.7) 
in M. bovis was observed in Anholt et al. [11] when resistance was assigned at a MIC ≥ 4 ug/mL. 
This seems disproportionately higher, given that florfenicol accounted for 35.4% of treatments. 
However, only 38% of animals had treatment records available. Overall, the antimicrobial 
susceptibility results indicate that populations of M.bovis are largely susceptible to florfenicol. 
As antimicrobials remain the only therapeutic option for control and treatment of 
mycoplasmosis, it is crucial that an appropriate antimicrobial is given at the correct dose and 
time for the right disease.  
Given that there was a single antimicrobial (florfenicol) to which 89.9% of M. bovis 
isolates were susceptible, the question should not be how best to use this antimicrobial but rather 
what other management practices could reduce M. bovis infections in feedlot cattle. Vaccines 
remain an ideal alternative to antimicrobials; however, the variability in the immunogenic 
surface proteins and lack of a suitable in vitro model have hindered the development of vaccines 
against M. bovis [7,78]. This leaves alternative management practices, such as ranch direct 
purchases and preconditioning of cattle as alternative mitigation strategies. Ranch-direct 
purchases are when cattle by-pass an auction mart and enter backgrounding operations directly 
from the cow-calf operation. Preconditioning is when stressful events and procedures are 
performed at the cow-calf operation to promote immunocompetency and to decrease the risk of 
respiratory disease [32,131]. Ranch direct purchases would reduce the commingling of cattle 
prior to arrival at the feedlot ultimately reducing the potential for transmission of M. bovis. 





disease from viral and/or bacterial infections. As preconditioning would occur in the cow-calf 
sector, the current lack of monetary incentive for producers to go this route unless ownership of 
the cattle is retained makes it less likely to be implemented. 
Despite the levels of antimicrobial resistance in M. bovis, banning the use of 
antimicrobials altogether is not a reasonable alternative as they provide a crucial therapeutic tool 
that directly impacts the welfare of animals. Given the use of multiple classes of antimicrobials, 
without the benefit of recovery from a M. bovis infection, studies to compare the timing of 
therapeutic intervention could be beneficial to assess the risks and rewards to their use against M. 
bovis. This could possibly lead to the development of earlier endpoints for euthanasia when 
attempting to treat a mycoplasmosis. Having earlier endpoints would be beneficial in two 
regards. It could reduce the overall administration of antimicrobials and would positively 
influence animal welfare by reducing the time cattle remain in the feedlot with pneumonia and/or 
arthritis that is not going to respond to antimicrobial intervention. 
The time consuming and labour intensive process of performing an in vitro based 
technique such as AST on M. bovis are caveats that limit the implementation of this method to 
make timely decisions on AMU. As an alternative, direct detection of the genotype is amenable 
to rapid molecular techniques such as PCR. Given the increased resistance and importance of 
macrolides in treatment and prevention of M. bovis related disease, Chapter 3 investigates the 
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 Mycoplasma bovis is associated with bovine respiratory disease (BRD) and chronic 
pneumonia and polyarthritis syndrome (CPPS) in feedlot cattle. No efficacious vaccines for M. 
bovis exist; hence, macrolides are commonly used to control mycoplasmosis. Whole genome 
sequences of 126 M. bovis isolates, derived from 96 feedlot cattle over 12 production years were 
determined. Antimicrobial susceptibility testing (AST) of five macrolides (gamithromycin, 
tildipirosin, tilmicosin, tulathromycin, tylosin) was conducted using a microbroth dilution 
method. The AST phenotypes were compared to the genotypes generated for 23S rRNA and the 
L4 and L22 ribosomal proteins. Mutations in domains II (nucleotide 748; E. coli numbering) and 
V (nucleotide 2059 and 2060) of the 23S rRNA (rrl) gene alleles were associated with resistance. 
All isolates with a single mutation at Δ748 were susceptible to tulathromycin, but resistant to 
tilmicosin and tildipirosin. Isolates with mutations in both domain II and V (Δ748Δ2059 or 
Δ748Δ2060) were resistant to all five macrolides. However, >99% of isolates were resistant to 
tildipirosin and tilmicosin, regardless of the number and positions of the mutations. Isolates with 
a Δ748 mutation in the 23S rRNA gene and mutations in L4 and L22 were resistant to all 
macrolides except for tulathromycin. 
3.2 Introduction 
Mycoplasma bovis is associated with various diseases of cattle such as pneumonia, 
mastitis, arthritis, otitis media, conjunctivitis, and reproductive disorders [6,45]. In feedlot cattle, 
M. bovis infections commonly manifest as bovine respiratory disease (BRD) and chronic 
pneumonia and polyarthritis syndrome (CPPS) [2,3]. Furthermore, M. bovis infections often 
respond poorly to antimicrobial therapy, resulting in a chronic infection [49]. This lack of a 
response frequently results in prolonged antimicrobial therapy, which indiscriminately selects for 
antimicrobial resistance in other pathogens that comprise the BRD complex [7]. Mycoplasmosis 
in the feedlot results in economic losses due to reduced production performance, increased 
treatment costs, and death loss [6,7]. In addition, feedlot cattle with polyarthritis may become 
severely lame, which is a significant animal welfare issue. 
As there are currently no effective vaccines for M. bovis, antimicrobials remain the 
primary option for prevention and control of mycoplasmosis [6,20]. This has led to a number of 





throughout Europe [14,16-21]. These studies suggest that M. bovis will continue to become 
increasingly resistant to antimicrobials. This situation is exacerbated by the limited number of 
antimicrobials available for treating mycoplasma infections. Mycoplasma spp. lack a cell wall 
and the ability to synthesize folate, rendering them intrinsically resistant to all β-lactams and 
sulfonamides [6]. In addition, most aminoglycosides either lack label claims for BRD, or the 
formulations are not amenable to use in feedlot cattle. This narrows the selection of 
antimicrobials to those that target protein synthesis or DNA replication, and that have been 
formulated to maintain therapeutic blood levels for several days. The main class of 
antimicrobials that meet these criteria is the macrolides.  
Macrolides have been formulated to be administered parenterally or in-feed; however, 
only one macrolide, tylosin tartrate (TYLT), is registered in Canada for in-feed use. Tylosin is 
typically administered throughout the feeding period, and is used to control liver abscesses [11]. 
The other four main macrolides used in the feedlot are: tilmicosin (TIL), tildipirosin (TIP), 
tulathromycin (TUL), and gamithromycin (GAM). All of which are formulated as long-acting 
injectable antimicrobials, and depending on the drug, may have label claims for the control 
(metaphylaxis) and treatment of BRD. A distinctive pharmacological characteristic of macrolides 
that makes them ideally suited for use in feedlot cattle is their predilection to concentrate in the 
pulmonary epithelial fluid [132]. This is notable because BRD is the most prevalent and costly 
disease of feedlot cattle [133]. Thus, the macrolides’ pharmacokinetic and pharmacodynamic 
profiles are particularly well suited for metaphylaxis therapy for BRD in feedlots [53]. In 
western Canada, cattle deemed to be a high risk for developing BRD often receive TUL at the 
time of arrival to the feedlot; whereas, low risk cattle may receive either no antimicrobials or a 
long-acting oxytetracycline [44]. Lastly, unlike other BRD pathogens, antimicrobial resistance in 
M. bovis is not associated with antimicrobial resistance genes [134], but rather resistance arises 
from mutations in ribosomal RNAs [4].  
Macrolides are a member of the macrolide–lincosamide–streptogramin B (MLSB) 
superfamily, all of which exert a bacteriostatic effect by disrupting protein synthesis [135]. 
Specifically, they bind with domains II and V of 23S rRNA, which is a component of 50S 
ribosomal subunit [63,136]. Ribosomal proteins L4 and L22 are positioned in close proximity to 





proteins are associated with macrolide resistance [4,137]. This mechanism of resistance is not 
unique to M. bovis [22,67,71], having been reported in a variety of bacterial species, including 
other Mycoplasma spp. [138,139], Neisseria gonorrhoeae [137], Streptococcus spp. [140,141], 
Francisella tularensis [142], Escherichia coli [143], Chlamydia trachomatis [144], and 
Haemophilus influenzae [145]. 
A limitation of antimicrobial susceptibility testing (AST) for M. bovis is the lack of 
established clinical breakpoints from the Clinical and Laboratory Standards Institute (CLSI) and 
the European Committee on Antimicrobial Susceptibility Testing (EUCAST). As a result, 
researchers have extrapolated M. bovis clinical breakpoints from human Mycoplasma spp. and 
other bovine respiratory pathogens for which clinical breakpoints have been established 
[11,12,15,16,28,29,116]. Another challenge with performing AST on M. bovis is its very 
fastidious culture requirements, which is related to its reduced genome and limited biosynthetic 
capacity [27]. These requirements, coupled with relatively slow nonprolific growth, have 
encouraged the development of rapid molecular testing techniques for predicting antimicrobial 
susceptibility for M. bovis [22,146]. Utilization of a genotypic approach to assess antimicrobial 
susceptibility of M. bovis could allow for more expeditious evaluation of antimicrobial efficacy 
and evidence-based selection of antimicrobials to enable judicious use of antimicrobials, which 
are all principles of antimicrobial stewardship. Additionally, a genotypic approach could be more 
amenable as a standardized approach to assess antimicrobial susceptibility in M. bovis than 
culture-based techniques, as it would not be susceptible to variable results due to growth 
conditions. To support these efforts, this study assessed the concordance between genotypes 
known to confer macrolide resistance to AST phenotypes. Specifically, the study compared the 
23S rRNA, L4, and L22 genotypes of M. bovis isolates to the AST results of five macrolides 
commonly used in western Canadian feedlot cattle to control and treat BRD. 
3.3 Materials and Methods 
3.3.1 Animals and Sample Collection 
Mycoplasma bovis isolates were cultured from a cross-section of clinical samples derived 
from different anatomical regions (nasopharynx, lung, and joint) of western Canadian feedlot 
cattle over 12 production years (2006–2018). Deep nasopharyngeal swabs from live cattle were 





University of Saskatchewan’s Animal Research Ethics Board and Lethbridge Research Center’s 
Animal Care Committee (#1641).  
Sampling was performed as described in Jelinski et al. [12]. Briefly, doubled-guarded 
uterine swabs (Reproduction Resources, Walworth, WI, USA) were used to obtain deep 
nasopharyngeal (DNP) samples from healthy and diseased cattle. The diseased cattle were 
identified by feedlot personnel trained in recognizing the clinical signs of BRD (dyspnea, 
depression, nasal discharge, anorexia, and fever). Swabs were immediately placed in Ames 
media (Mai, Ames Media, Product 49203, Spring Valley, WI, USA). 
All other swabs or tissues were collected from animals purposively sampled by feedlot 
veterinarians recruited to provide clinical case material for the study. Samples were obtained by 
the veterinarians from animals that on postmortem examination were found to have pathological 
lesions consistent with M. bovis pneumonia or chronic pneumonia and polyarthritis syndrome 
(CPPS). Specifically, the lungs had gross pathology consistent with caseonecrotic pneumonia 
and/or chronic bronchopneumonia. A minimum 3 × 3 cm lung sample was excised and if septic 
arthritis was concurrently observed, then the diseased joints were sampled by swabbing, 
aspirating synovial fluid, or excising synovial tissue.  
Tissue and fluid specimens were stored at –20 °C, and batch shipped by courier. Upon 
receipt, samples were stored at –80 °C until culturing. For each sample, the following metadata 
were recorded: date of sampling, type of sample (swab, tissue, joint fluid), anatomical location 
(nasopharynx, lung, joint), and disease status (healthy, diseased, dead).  
3.3.2 Mycoplasma Culture and Isolation 
Selective culture was performed on the DNP swabs and on swabs of the cut tissue 
surfaces as previously described by Jelinski et al. [12]. Due to the extended time span of sample 
collection, there were slight differences in isolation methods and media over the course of the 
study. Samples collected between 2006 to 2008 were cultured using Hayflick’s media (made in -
house), whereas in subsequent years samples were cultured using pleuropneumonia-like 
organism (PPLO) broth and agar (BD Difco, Fisher Scientific, Waltham, MA, USA) , 
supplemented with 10 g/L yeast extract (BD Diagnostic Systems, Fisher Scientific, Waltham, 





media was supplemented with 0.05% thallium (I) acetate, 500 U/mL penicillin G, and/or 0.5% 
sodium pyruvate (Sigma-Aldrich, St. Louis, MO, USA). 
Cultures derived from samples were filtered through 0.45 and 0.20 µm filters (Basix, 
VWR International, Radnor, PA, USA), and were used to inoculate PPLO broth with  0.05% 
thallium (I) acetate, 500 U/mL penicillin G, and 0.5% sodium pyruvate, and grown in a 5% CO2 
atmosphere with 75% humidity at 37 °C. Cultures with visible growth were streaked onto PPLO 
agar with 0.05% thallium (I) acetate and 500 U/mL penicillin G and incubated for 3-6 days. An 
isolated colony with characteristic “fried-egg” morphology was picked, replated on PPLO agar, 
and incubated for 72 h. Up to three individual colonies per sample were used to inoculate 
separate aliquots of PPLO broth with 0.05% thallium (I) acetate and 500 U/mL penicillin G. 
After 48 h of growth, each culture was separately stored in PPLO with glycerol (20%, v/v) at –80 
°C. From the three possible cultures, a single culture was chosen to inoculate PPLO media for 
DNA extraction and antimicrobial susceptibility testing. 
3.3.3 DNA Extraction and Identification 
Mycoplasma bovis isolates were grown in PPLO media for 48 h and the genomic DNA 
was extracted using the GenElute Bacterial Genomic DNA Kit (Sigma-Aldrich, St. Louis, MO, 
USA). The DNA was extracted following manufacturer’s instructions for Gram negative bacteria 
with the final elution buffer replaced with 10 mM Tris (pH 8.5). Extracted genomic DNA was 
assessed for quality using gel electrophoresis and quantified fluorometrically using Qubit 
(Thermo Fisher Scientific, Waltham, MA, USA). Cultures were confirmed as M. bovis, based on 
confirmation of the presence of uvrC [35] and sequencing of the 16S rRNA gene [129]. The 16S 
rRNA amplicon was purified using a QIAquick PCR purification kit (Qiagen, Nevlo, 
Netherlands) and sent to Macrogen (Seoul, South Korea) for Sanger sequencing with the 
amplification primers. Forward and reverse sequences were assembled and edited using the 
Staden Package (version 1.6-r, http://staden.sourceforge.net/). The resulting sequences were 
compared to the National Center for Biotechnology Information (NCBI) nonredundant 
nucleotide database (nr) using BLASTn. 
3.3.4 Whole Genome Sequencing and Assembly 
Genomic DNA was prepared for sequencing using Illumina Nextera XT DNA Library 





using the MiSeq v2 Reagent Kit to generate 250 bp paired-end reads. Illumina reads were 
trimmed using Trimmomatic v0.38 [147] with settings slidingwindow:5:15 leading:5 trailing:5 
and minlen:50. Genomes were assembled with M. bovis PG45 as the reference genome 
(CP002188) using BWA-MEM v0.7.10-r789 [148] with default settings, producing SAM 
formatted assemblies. SAMtools [149] was used to convert the assemblies to BAM files and then 
sort and index for further processing. The Picard v2.18.4-SNAPSHOT [150] marked and 
removed duplicate reads from the BAM file. The Genome Analysis ToolKit v3.4-46-gbc02625 
was used to perform local indel realignment and base quality score recalibration to improve the 
alignment quality, according to GATK best practices pipeline [151]. Consensus sequences for 
each assembly were created from each BAM file using bcftools [149]. This was performed by 
piping results from bcftools mpileup to bcftools call to create a vcf file for each BAM file. Each 
vcf file was used as input for vcfutils vcf2fq to generate a consensus fastq file. The fastq files 
were converted to fasta files using a bash script. 
Genes encoding for 23S rRNA (rrl3 and rrl4), L4 (rplD), and L22 (rplV) ribosomal 
proteins were identified using BLASTn [152] to compare M. bovis strain PG45 genes to the 
assembled genomes. For rrl3 and rrl4, the closest matching sequence to the start of the genome 
being analyzed was identified as rrl3, the furthest as rrl4. As two start sites have been proposed 
for ribosomal protein L4, for the purposes of this study the position of rplD and overall 
numbering was based on locus ID MBOVPG45_0263. Extraction of gene sequences was 
performed using the start and ends of the match as reported by BLASTn for input to SAMtools 
faidx [149]. Genes of interest extracted from each isolate were aligned with the equivalent region 
in the M. bovis PG45 reference genome (CP002188.1) in Geneious Prime 2020.0.5 
(https://www.geneious.com) using MUSCLE to identify SNPs with a minimum variant 
frequency of 0.01. For L4 and L22 ribosomal protein gene alignments, they were translated using 
the Mycoplasma spp. genetic code. To verify the nucleotide composition in rrl3 and rrl4 at 
positions within hairpin 35 in domain II and the peptidyl transferase loop in domain V within the 
MLSB binding pocket [153], the SAM files were queried for ambiguity to determine the 
representative nucleotide(s). In cases of ambiguity, the percent of reads for a given allele was 
>20%. The raw paired reads for the isolates used in this study are available at NCBI SRA 





The M. bovis sequences were aligned to their respective 23S rRNA (rrlA), L4 (rplD), or 
L22 ribosomal protein (rplV) genes isolated from the E. coli K12 substrain MG1655 genome to 
determine equivalent positioning to generate numbering to allow for comparison between 
different studies and bacterial species. 
3.3.5 Antimicrobial Susceptibility Testing 
Antimicrobial susceptibility (AST) was determined using a microdilution assay, in a 
Sensititre™ (Trek Diagnostics, Oakwood, GA, USA) plate format and a customized panel 
designed to assess the antimicrobials most commonly used in North American feedlots for the 
treatment and control of BRD. The panel consisted of ten antimicrobials as described by Jelinski 
et al. [12], five of which were macrolides: tildipirosin (TIP; 0.12–128 µg/mL), gamithromycin 
(GAM; 0.25–256 µg/mL), tulathromycin (TUL; 0.25–256 µg/mL), tilmicosin (TIL; 1–256 
µg/mL), and tylosin tartrate (TYLT; 1–128 µg/mL). AlamarBlue (ThermoFisher Scientific, 
DAL1100), a color redox indicator, was used to assess growth in each well based on a blue to 
pink color transition. 
The AST procedure began by inoculating an M. bovis isolate previously stored at –80 °C 
in 20% glycerol into PPLO broth with 0.5% pyruvate and incubating for 72 h at 5% CO2 with 
75% humidity at 37 °C. Broth cultures were then subcultured into neat PPLO (without 
antibiotics) and incubated for 24 h. Following incubation, the optical density (OD) at 450 nm 
was determined using a NanoDrop One Spectrophotometer (Fisher Scientific, Waltham, MA, 
USA) and the culture adjusted to an OD450 = 0.1. The adjusted culture was diluted up to 100X, 
and 120 µL of the diluted culture used to inoculate 6 mL of PPLO in 2X alamarBlue. Each well 
of a Sensititre™ plate was inoculated to a final concentration of 103 to 5 × 105 CFU/mL with 50 
µL of culture in 2X alamarBlue in 50 µL of media with each of antimicrobials within a series of 
Sensititre wells (final working concentration of alamarBlue: 1X; final well volume: 100 µL). 
Plates were sealed with a CO2 permeable film, and incubated for 48–72 h. Minimum inhibitory 
concentrations (MICs) were determined by visual assessment of plates at 48 and 72 h, based on a 
blue to pink colour change. The M. bovis reference strain (Mycoplasma bovis ATCC® 25523™) 





3.3.6 Clinical Breakpoints 
As there are no established macrolide breakpoints for M. bovis, they were extrapolated 
from other members of the bacterial BRD complex (i.e., Mannheimia haemolytica, Pasteurella 
multocida, Histophilus somni) and human Mycoplasma spp., as described previously in Jelinski 
et al. [12]. The resistance breakpoints were ≥ 8 µg/mL for TIP, GAM, TIL, and TYLT, and ≥32 
µg/mL for TUL. 
3.3.7 Statistical Analysis 
As rrl3 and rrl4 genes in the reference sequence for M. bovis PG45 differ by only a 
single nucleotide, alleles in each isolate could not be assigned to a specific locus. Instead, 
allele(s) at a given position were reported and isolates were grouped into genotypes according to 
the presence of mutation(s) in domain II and V. This created four 23S rRNA genotype groups: 
wildtype, Δ748 only, Δ748Δ2059, and Δ748Δ2060. 
As phenotypically resistant and susceptible isolates were derived from cattle in each 
health status cohort (healthy, diseased, and dead), all isolates were analyzed together regardless 
of their source. Confidence intervals were calculated using the Wilson score interval method for 
estimating intervals for proportions. The confidence intervals were used to represent the 
antimicrobial resistance for a given 23S rRNA genotype using Epitools [154]. To assess the 
agreement in classification of resistance between the presence of a mutation in domain V of the 
23S rRNA genotype and phenotype (MIC value), the Cohen’s kappa statistic interpretation 
criteria (value, level of agreement): 0–0.20, none; 0.21–0.39, minimal; 0.40–0.59, weak; 0.60–
0.79, moderate; 0.80–0.90, strong; > 0.90, almost perfect [155] were calculated using a 
commercial statistical program (SPSS 26, IBM SPSS Statistics version 26, IBM Corporation, 
Armonk, NY, USA). All descriptive statistics were calculated using a commercial spreadsheet 
software (Microsoft Excel version 15; Microsoft Corporation, Redmond, Washington, WA, 
USA). 
3.4 Results 
3.4.1 Culture and Reference Antimicrobial Susceptibilities 
A total of 126 Mycoplasma bovis isolates were derived from 96 head of feedlot cattle 
from 21 feedlots over 12 production years, 2006 to 2018 (Table 3.1). Thirty head of cattle 





and 47 isolates came from the nasopharynx. Nasopharyngeal isolates were derived from healthy 
(n = 30), diseased (n = 15), and dead (n = 2) cattle. Phenotypically resistant isolates to the 
macrolides tested were derived from samples taken from healthy, diseased, and dead cattle 
(Table 3.2). Production years were used to define the sampling cohort, as animals often enter the 
feedlot in the fall and remain until the following calendar year. Thus, the 2018 production year 
included samples obtained between 1 November 2018 and 30 June 2019. 
Mycoplasma bovis PG45 (Mycoplasma bovis ATCC® 25523) was resequenced and 
possessed the equivalent 23S rRNA genotype at positions 748, 2059, and 2060, as reported in the 
published reference genome [76, CP002188.1]. Compared to the published reference genome, no 
nonsynonymous mutations in L4 and L22 ribosomal proteins were observed in this resequenced 
isolate. The following minimum inhibitory concentration (MIC) values, defined as the lowest 
concentration of antimicrobial to visibly inhibit growth, were determined from AST of five PG45 
replicates: GAM, 8–16; TIP, 4–8; TIL, 1; TUL, 0.25; and TYLT, 1–2 µg/mL. Due to these 
genotypic and phenotypic findings, M. bovis PG45 was considered to be a susceptible wildtype 
isolate. 
 




2006 2007 2008 2014 2015 2016 2017 2018 Total 
Anatomical Location          
Joint  1 1 1 1 14 11 6 35 
Lung    3 3 17 15 6 44 
Nasopharynx 5 28     9 5 47 
Total 5 29 1 4 4 31 35 17 126 
Health Status          
Healthy 2 14     9 5 30 
Diseased 3 12       15 
Dead  3 1 4 4 31 26 12 81 






Table 3.2 Number of Mycoplasma bovis isolates (n = 126) with a resistant (R) or susceptible (S) 
phenotype by health status. 
Health Status 
Phenotype (% Resistant) 

























































GAM—gamithromycin, TIL—tilmicosin, TIP—tildipirosin, TUL—tulathromycin, and TYLT—
tylosin. 
3.4.2 Genome Sequencing and Assembly 
Draft genomes of the 126 isolates were assembled from an average 210113 paired reads 
(range: 55951 to 414042); average read length of 217 bp (range: 166 to 233 bp). This produced 
assemblies with an average N50 of 18690 bp (range: 1780 to 34113 bp), an average coverage 
depth of 45.3 (range 12.2 to 89.1), and an average of 579 contigs (range: 171 to 1639). 
3.4.3 23S rRNA gene 
Among the 126 isolates analyzed, mutations (single nucleotide polymorphisms, SNPs) 
were located in hairpin 35 of domain II (nucleotide 748; E. coli numbering used throughout) and 
the peptidyl transferase loop of domain V (nucleotide 2059 and 2060) of the 23S rRNA (rrl) gene 
alleles. The 23S rRNA genotype was assigned based on alleles observed at position 748, 2059, 
and 2060 (Table 3.3). As there are up to two copies of the rrl gene reported for M. bovis, an 
isolate was categorized as having a change (Δ) if a mutation occurred in at least one copy of the 
gene. The M. bovis PG45 reference genome was considered as the reference (wildtype) and two 
isolates (1.6%) were identical to this 23S rRNA genotype. Most isolates (73.0%; 92/126) had 
mutations in domains II and V (Δ748Δ2059 or Δ748Δ2060); whereas, 25.4% (32/126) had a 





All isolates with a single mutation at Δ748 were susceptible to TUL (MIC ≤ 16 µg/mL); resistant 
to TIP and TIL (MIC ≥ 8 µg/mL); and either susceptible (MIC ≤ 4 µg/mL) or resistant (MIC ≥ 8 
µg/mL) to GAM and TYLT (Figure 3.1a). Isolates that had accumulated mutations in both 
domain II and V (Δ748Δ2059 or Δ748 Δ2060) were resistant to all five macrolides (Table 3.3 
and Figure 3.1b).  
No dose dependent effect was apparent within a given genotype (i.e., Δ748 only) for 
those with a single mutant allele (i.e., G748A) or a combined mutant/wildtype allele (i.e., G748, 
G748A). The MIC values for isolates with Δ748 only 23S rRNA genotype, with a single mutant 
allele, ranged from 1 to 128 µg/mL for GAM and TYLT, and 0.25 to 8 µg/mL for TUL. Isolates 
with combined alleles had consistently lower MIC values of 8, 8–16, and 0.25 µg/mL for GAM, 
TYLT, and TUL, respectively, which were within the MIC range for isolates with a single 
mutant allele. For isolates with the Δ748Δ2059 23S rRNA genotype, those with combined alleles 
had MIC values ranging from 8 to ≥ 128 µg/mL for TYLT compared to ≥ 128 µg/mL with a 
single mutant allele. Regardless of allelic composition, the MIC values for isolates with 




Table 3.3 Comparison of 23S rRNA genotypes and the number (%) of Mycoplasma bovis isolates (n = 126) resistant to the 
five macrolides tested. 
Genotype 
23S rRNA gene alleles+ 
Percent (n) of isolates 
Phenotype# (% Resistant) 
Domain II Domain V 
GAM TIL TIP TUL TYLT 
748 2059 2060 
Wildtype* G748 A2059 A2060 1.6 (2) 1 (50) 1 (50) 2 (100) 0 (0) 0 (0) 
Total 1.6 (2) 1 (50) 1 (50) 2 (100) 0 (0) 0 (0) 
Δ748 only 
G748, G748A‡   4.0 (5) 5 (100) 5 (100) 5 (100) 0 (0) 5 (100) 
G748A    21.4 (27) 8 (29.6) 27 (100) 27 (100) 0 (0) 14 (51.9) 
Total 25.4 (32) 13 (40.6) 32 (100) 32 (100) 0 (0) 19 (59.4) 
Δ748Δ2059 
G748, G748A‡ A2059, A2059G‡  0.8 (1) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 
G748A A2059, A2059G‡  2.4 (3) 3 (100) 3 (100) 3 (100) 3 (100) 3 (100) 
G748A A2059, A2059C‡  2.4 (3) 3 (100) 3 (100) 3 (100) 3 (100) 3 (100) 
G748A A2059, A2059T‡  7.1 (9) 9 (100) 9 (100) 9 (100) 9 (100) 9 (100) 
G748A A2059G  49.2 (62) 62 (100) 62 (100) 62 (100) 62 (100) 62 (100) 
Total 61.9 (78) 78 (100) 78 (100) 78 (100) 78 (100) 78 (100) 
Δ748Δ2060 
G748A  A2060, A2060C‡ 0.8 (1) 1 (100) 1 (100) 1 (100) 1 (100) 1 (100) 
G748A  A2060C 7.9 (10) 10 (100) 10 (100) 10 (100) 10 (100) 10 (100) 
G748A  A2060G 2.4 (3) 3 (100) 3 (100) 3 (100) 3 (100) 3 (100) 
Total 11.1 (14) 14 (100) 14 (100) 14 (100) 14 (100) 14 (100) 
* Mycoplasma bovis PG45 is designated as wildtype genotype. # GAM—gamithromycin, TIL—tilmicosin, TIP—tildipirosin, 
TUL—tulathromycin, and TYLT—tylosin. ‡ Representative of a combined wildtype and mutant allele.+ Positioning of the 






Figure 3.1 Minimum inhibitory concentrations (MIC) of Mycoplasma bovis isolates (n = 126) for tylosin (TYLT), tilmicosin (TIL), 
tildipirosin (TIP), gamithromycin (GAM), and tulathromycin (TUL), and the corresponding 23S rRNA genotype: a) wildtype (wt) or 
mutations in domain II only (Δ748); b) mutations in domain II and V (Δ748Δ2059, Δ748Δ2060). The MIC values for the five M. 
bovis PG45 replicates [wt(PG45)] are presented. TYLT, TIL, and TIP have a 16-membered core structure; whereas, GAM and TUL 
have a 15-membered core structure
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The 23S rRNA genotypes were grouped based on the presence of mutations in domain II 
only versus domain II and V. The results were reported as % resistant with 95% confidence 
interval (95% CI) for a proportion (Table 3.4). The two isolates with wildtype 23S rRNA 
genotypes were susceptible to TUL and TYLT (0, 0–0.66), and 1 of 2 were resistant to GAM and 
TIL (0.5, 0.09–0.91). Isolates with mutations in domain II only (Δ748 only) had a similar 
proportion of isolates resistant to GAM (0.41, 0.26–0.58) and TYLT (0.59, 0.42–0.74) compared 
to TUL (0, 0–0.11). An additional mutation in domain V at positions 2059 (Δ748Δ2059) or 2060 
(Δ748Δ2060) resulted in all isolates being resistant to all five macrolides. All isolates were 




















Table 3.4 Number and proportion of Mycoplasma bovis isolates (n = 126) resistant (R) or 
susceptible (S) by 23S rRNA genotype. The 95% binomial proportion confidence interval 
(Wilson score) is an interval estimate of the probability of the isolate being resistant if it has a 
particular 23S rRNA genotype. 
 
23S rRNA Genotype+ 
Wildtype Δ748 only Δ748Δ2059 Δ748Δ2060 
TUL R/S 0/2 0/32 78/0 14/0 
Proportion (95% CI) 0 (0 – 0.66) 0 (0 – 0.11) 1 (0.95 – 1) 1 (0.78 – 1) 
GAM R/S 1/1 13/19 78/0 14/0 
Proportion (95% CI) 0.50 (0.09 – 0.91) 0.41 (0.26 – 0.58) 1 (0.95 – 1) 1 (0.78– 1) 
TYLT R/S 0/2 19/13 78/0 14/0 
Proportion (95% CI) 0 (0 – 0.66) 0.59 (0.42 – 0.74) 1 (0.95 – 1) 1 (0.78 – 1) 
TIL R/S 1/1 32/0 78/0 14/0 
Proportion (95% CI) 0.50 (0.09 – 0.91) 1 (0.89 – 1) 1 (0.95 – 1) 1 (0.78 – 1) 
TIP R/S 2/0 32/0 78/0 14/0 
Proportion (95% CI) 1 (0.34 – 1) 1 (0.89 – 1) 1 (0.95 – 1) 1 (0.78 – 1) 
Total 2 32 78 14 
GAM—gamithromycin, TIL—tilmicosin, TIP—tildipirosin, TUL—tulathromycin, and TYLT—
tylosin.+ Positioning of the alleles is based on Escherichia coli numbering. 
 
The level of agreement in the classification of resistance between the presence of a 
mutation in domain V in the 23S rRNA genotype and phenotype (MIC values) varied by 
macrolide. The kappa correlation coefficient was perfect (1.000) for TUL, moderate (0.676) for 
GAM, weak (0.536) for TYLT, essentially nonexistent (0.042) for TIL, and could not be 
determined for TIP because all isolates were resistant regardless of the genotype. Despite these 
differences, all isolates with a mutation in domain V of the 23S rRNA genotype (Δ748Δ2059 
and Δ748Δ2060) were resistant to all macrolides. However, mutations in domain V also occurred 
in the presence of a mutation in domain II at position 748. 
3.4.4 L4 and L22 Ribosomal proteins 
All isolates had a nonsynonymous mutation Gln93His (M. bovis PG45 number; 
equivalent to Gln90His using E. coli numbering) in the L22 ribosomal protein. There were 
multiple nonsynonymous L4 mutations: Ser18Thr, Thr43Ala, Ala44Thr, Glu50Thr, Ala51Thr, 
Ala51Ser, Ser55Ala, Thr57Ala, Val69Ala, Ala70Thr, Glu75Ala, Ala86Thr, and Ala101Thr (M. 





proximity to the MLSB binding pocket Gly185Arg, Gly185Ala, Thr186Pro (M. bovis PG45 
numbering; equivalent to position 64 and 65 using E. coli numbering, respectively). 
Twelve isolates had a nonsynonymous mutation in the L4 ribosomal protein in residues 
proximal to the MLSB binding pocket. Four had two nonsynonymous mutations Gly185Ala and 
Thr186Pro, and eight had a single nonsynonymous mutation Gly185Arg (Table 3.5). All isolates 
had Gln93His mutations in L22 as well. All isolates with the two nonsynonymous mutations 
(Gly185Ala and Thr186Pro) also had mutations in domain II of the 23S rRNA gene (Δ748). The 
eight isolates with a single nonsynonymous mutation (Gly185Arg) had various 23S rRNA 
genotypes: wildtype (n = 1), Δ748 (n = 1), and Δ748Δ2059 (n = 6). Overall, isolates with a Δ748 
mutation in the 23S rRNA gene and mutations in L4 and L22 near the MLSB binding pocket 
were resistant (MICs ≥16 µg/mL) to GAM, TIL, TIP and TYLT; but susceptible (MICs ≤8 


















Table 3.5 Presence of ribosomal protein mutations in different 23S genotype groups and 
corresponding minimum inhibitory concentrations (MIC) values. 
23S rRNA Genotype+ 
MIC (µg/mL) Ribosomal Proteins‡ 
GAM TIL TIP TUL TYLT L4 L22 
wildtype (PG45) 8–16 1 4–8 0.25 1–2 Gly185, Thr186 Gln93 
wildtype 32 64 >128 1 4 Gly185Arg Gln93His 
Δ748 
128 >256 >128 2 128 Gly185Ala, Thr186Pro Gln93His 
128 >256 >128 8 128 Gly185Ala, Thr186Pro Gln93His 
64 >256 >128 0.5 64 Gly185Ala, Thr186Pro Gln93His 
64 >256 >128 1 64 Gly185Ala, Thr186Pro Gln93His 
16 256 128 0.25 32 Gly185Arg Gln93His 
Δ748Δ2059 
>256 >256 >128 >256 >128 Gly185Arg Gln93His 
>256 >256 >128 256 >128 Gly185Arg Gln93His 
>256 >256 >128 >256 >128 Gly185Arg Gln93His 
>256 >256 >128 128 64 Gly185Arg Gln93His 
>256 >256 >128 128 64 Gly185Arg Gln93His 
>256 >256 >128 32 64 Gly185Arg Gln93His 
+ Positioning of the alleles is based on Escherichia coli numbering. 
‡ Positioning of amino acids is based on Mycoplasma bovis PG45 numbering. 
 
3.5 Discussion and Conclusion 
This study was unique in that it assessed the concordance between the genotypes and 
phenotypes of M. bovis for antimicrobial resistance (AMR) to five macrolides used to control 
and treat bovine respiratory disease in feedlot cattle. Of note was the inclusion of TUL, which is 
the most commonly used antimicrobial for BRD prophylaxis, but a pharmaceutical that has not 
been assessed in previous genotype–phenotype AMR studies [22,67,69,71]. This is salient 
because even though macrolides have a similar antibacterial mode of action, they differ in the 
size of the macrocyclic lactone ring and associated side-chains [59]. As a result, each macrolide 
has a slightly different binding affinity for domains II and V of 23S rRNA. Thus, one or more 
mutations within these domains may lead to very different antimicrobial susceptibility testing 
(AST) results. Exemplars are TUL, TIL, and TIP, where a single mutation in domain II (Δ748) 
conferred resistance to TIL and TIP, but not to TUL. This is consistent with the modeling of the 





span the ribosomal tunnel and interact with G748 in domain II [59]. This finding is of interest 
because previous genotype studies did not include TUL.  
Within the 23S rRNA gene, mutations in domain V occurred at position 2059 or 2060, 
but not both. In contrast, Lerner et al. [71] identified two isolates with mutations in both rrl 
alleles in domain V, but at different positions (2058 and 2059). Furthermore, others have 
reported mutations at position 2058 in M. bovis [69,71,156], an outcome that was not found in 
the current study. Isolates with differing alleles at a given position in domain V were resistant to 
all five macrolides, which is consistent with a previous study in which Mycoplasma spp. having 
a heterozygous mutation in domain V conferring resistance [138]. Additionally, mutations at 
position 2060 have been reported in M. bovis isolates that are resistant to lincomycin [67], an 
antimicrobial with a mechanism of action similar to macrolides [20,135]. These differences in 
position, albeit in close proximity to one another, could reflect differences in the selective 
pressure of specific antimicrobials as a result of differences in use across production systems.  
Despite these differences, the increased resistance of M. bovis to macrolides as a result of 
mutations in domain II and domain V is consistent with previous reports [22,67,69,71]. 
Overall, concordance was observed between 23S rRNA genotype and AMR phenotype, 
which highlights the utility of molecular targets as a viable alternative to in vitro AST. Isolates 
with combined mutations in domain II and V binding sites of 23S rRNA gene (Δ748Δ2059 and 
Δ748Δ2060) all demonstrated resistance to TUL, GAM, and TYLT. Whereas regardless of 
genotype, >99% of all isolates were resistant to TIP and TIL. The accumulation of SNPs in 
domain II and V of the 23S rRNA gene and the relationship to increasing MIC values, and 
therefore inferred resistance, has been reported for TYLT and TIL in M. bovis by Hata et al. [22]. 
Lui and Douthwaite [157] also demonstrated that monomethylation at positions G748 and A2058 
acted synergistically to increase TYLT resistance. In both the Lerner et al. [71] study and the 
current study, the existence of mutations in both the II and V domains correlated with MICs for 
TYLT and TIL that were indicative of clinical resistance. However, it has also been reported that 
some M. bovis isolates with elevated MICs to TYLT and TIL only have a mutation in domain V, 
without a concurrent mutation at position 748 [69,71], while others had a change at 748 without 





Given that TIP and TIL are both derivatives of TYLT, the similarities in the level of 
resistance to these macrolides is not surprising. These three macrolides vary in the groups that 
decorate C5, C6, and C14 of their shared 16-membered core structure. As high levels of 
resistance (>99%) to both TIL and TIP was present, it was difficult to correlate phenotype and 
genotype. However, as per previous reports [11,13,17,18] the very high MIC values for these 
two antimicrobials indicate that they are unsuitable for treating mycoplasmosis in cattle.  
The associations of mutations in the L4 and L22 ribosomal proteins with susceptibility 
phenotypes were less clear than those of domains II and V of the 23S rRNA gene. Zhao et al. 
[158] reported that mutations in these ribosomal proteins lead to increased macrolide resistance 
in M. pneumonia. In the current study, mutations in L4 and L22 were associated with elevated 
MICs for GAM, TYLT, TIP, and TIL. Given that these ribosomal proteins f orm the narrowest 
constriction of the protein exit tunnel [159], with both having loops that extend adjacent to 
macrolide binding sites [160], the presence of mutations is consistent with the AST phenotypes. 
All isolates (n = 126) also had mutations in L22 relative to the type strain, a result more 
prevalent than reported by Lerner et al. [71], where the nonsynonymous mutation Gln90His (E. 
coli numbering) in L22 was observed in 75% of isolates. Again, these differences across studies 
are likely related to increased antimicrobial selection pressure placed on the western Canadian 
isolates. 
There was a very low prevalence of the M. bovis type strain PG45 genotype (1.6%) in 
this study compared to Hata et al. [22], who observed this genotype in 12.3% of 203 bovine 
isolates from Japan. Lerner et al. [71] found that this genotype in about half of the 54 isolates 
from cattle originating in the Middle East, Europe, and Australia. Variation in the proportion of 
wildtype M. bovis isolates circulating within cattle populations is undoubtedly related to 
differences in cattle production systems and antimicrobial use. In western Canada, most beef 
calves are weaned in the fall of the year and sold at auctions where they are commingled with 
cohorts from other farms. These newly weaned calves are then transported to feedlots where they 
are processed on-arrival. In addition to these stressors, these events occur when the weather 
canalso be inclement. Therefore, calves deemed to be at high-risk of developing BRD are 
administered macrolides, often TUL, on-arrival. Our data indicate that over time this practice has 





Significantly, not only has macrolide resistance in western Canadian feedlot cattle been 
increasing over the last few decades,it is also not uncommon to recover macrolide resistant M. 
bovis isolates from the nasopharynx of healthy cattle at feedlot arrival [12]. While feedlots could 
rotate macrolides with tetracyclines or florfenicol, as a strategy to reduce resistance, this practice 
requires timely AST data or otherwise it may exacerbate antimicrobial resistance. 
The study had a number of potential weaknesses. The wildtype 23S rRNA genotype 
essentially served as a control group; however, there were only two isolates in this group. This 
was unfortunate since one of two wildtype isolates were resistant to GAM and TIL, and both 
resistant to TIP. Additionally, control testing of healthy animals was not performed at the time of 
sampling diseased or dead animals. However, this study was not intended as a survey of 
macrolide susceptibility, but rather an investigation of the relationship between genotype and 
phenotype. Therefore, the healthy animals were sampled with the intent of culturing 
phenotypically susceptible isolates to serve as a basis of comparison to the abundance of resistant 
isolates derived from dead cattle. The other weaknesses were that the isolates were not uniformly 
spread over all 12 production years, and most isolates came from dead animals that had received 
extensive antimicrobial therapy prior to death. The study, however, also had some notable 
strengths. The relatively large number of isolates came from cattle that were sourced from a 
broad geographic area; samples were collected over 12 production years; from multiple 
anatomical locations; and from healthy, diseased and dead cattle.  
Conventional antimicrobial susceptibility testing for M. bovis is time-consuming and 
technically demanding, making it unsuitable for monitoring antimicrobial resistance in real-time 
within a feedlot. This is an issue because prudent use guidelines for antimicrobial use are 
predicated on AST. This study, and others, have shown a clear linkage between genotypes and 
macrolide resistance, providing an avenue for developing a rapid, accurate, and cost-effective 
molecular based test for M. bovis, similar to what has been done for Mycoplasma genitalium 
[139,161,162]. This test could be used to assess M. bovis isolates obtained from nasopharyngeal 
swabs, or for conducting pen-level AST surveillance by testing isolates found in shared watering 
bowls.  
Given that antimicrobials are the primary preventative and therapeutic tool to combat M. 





crucial to maintaining the utility of these drugs and facilitating antimicrobial stewardship 
practices. However, the comparatively slow growth of M. bovis yields longer turn-around times 
when exclusively using culture-based methods of assessment, which can impede timely decision 
making on antimicrobial use. In our study, we were able to identify mutations in domains II and 
V of the 23S rRNA genes that are associated with increased resistance to macrolides which show 
a clear linkage between genotype and phenotypic macrolide resistance (AST). These findings 
add strong support for utilizing rapid, accurate, and cost-effective molecular based tests for 
assessing the susceptibility of M. bovis to macrolides. 
Not only can WGS be used to investigate genotypes associated with AMR, but it is 
amenable to various in silico typing methods. As the ability to categorize and differentiate 
isolates is the cornerstone of epidemiological surveillance [120], the study outlined in Chapter 4 
utilizes four in silico genotyping methods (MLST, cgMLST, cgSNV, wgSNV) to assess the 
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Mycoplasma bovis is a significant pathogen of feedlot cattle, responsible for chronic 
pneumonia and polyarthritis syndrome (CPPS). M. bovis isolates (n = 129) were used to compare 
four methods of phylogenetic analysis, and to determine if the isolates’ genotypes were 
associated to phenotypes. Phenotype (metadata) included the health status of the animal from 
which an isolate was derived (healthy, diseased, dead); anatomical location (nasopharynx, lung, 
joint); feedlot; and production year (2006 to 2018). Four in-silico phylogenetic typing methods 
were used in the analyses: multilocus sequence typing (MLST), core genome MLST (cgMLST), 
core genome single nucleotide variant (cgSNV) analysis, and whole genome SNV (wgSNV) 
analysis. Using Simpson’s Diversity Index (D) as a proxy for resolution, MLST had the lowest 
resolution (D = 0.932), with cgSNV (D = 0.984) and cgMLST (D = 0.987) generating 
comparable results, while wgSNV (D = 1.000) provided the greatest resolution. Visual 
inspection of the minimum spanning trees found that the memberships of the clonal complexes 
and clades shared a similar structural appearance using cgMLST, cgSNV and wgSNV analyses. 
Although MLST had the lowest resolution, this methodology was intuitive, easy to apply, and 
the PubMLST database facilitates comparison of sequence types across studies. The cg methods 
had improved resolution over the MLST and the graphical interface software was user-friendly 
for non-bioinformaticians, but the proprietary software is relatively costly. wgSNV was the most 
robust for processing poor quality sequence data, while offering the highest resolution, but 
application of its software required specialized training. None of the four methods could 
associate genotypes to phenotype. 
4.2 Introduction 
Mycoplasma bovis is associated with a plethora of diseases in cattle, with reviews on this 
subject commonly emphasizing its role in chronic pneumonia, mastitis, and arthritis [4,6,45] . 
While the incidence of M. bovis-mastitis in Canada is relatively low [163,164], it is considered 
an emerging disease of dairy cattle [165]. The incursion of M. bovis into New Zealand, and the 
country’s considerable efforts to eradicate this organism, underscores its potential to cause 
significant economic losses to the dairy industry. In the feedlot industry, M. bovis is associated 
with bovine respiratory disease (BRD) and chronic pneumonia and polyarthritis syndrome 
(CPPS) [3]. However, its role in the pathogenesis of BRD has been equivocal. In the early 1990s, 





the pathogenesis of other bacterial BRD agents [166, 167]. It is now considered a primary 
pathogen of pneumonia in preweaned calves [99], and an opportunistic pathogen of BRD in 
feedlot cattle [3,6,45]. Cattle are frequently asymptomatic carriers, with the organism being 
recovered from the nasal passages of healthy cattle [99,168, 169]. It is hypothesized that 
stressors such as transport, commingling, and adverse climactic conditions trigger a stress 
response, resulting in elevated levels of glucocorticoids that may impair the immune response, 
allowing for increased bacterial shedding and clinical disease [170].  
A number of molecular techniques have been used for typing M. bovis isolates. 
Formative techniques include pulsed field gel electrophoresis (PFGE) [2,171,172], random 
amplified polymorphic DNA (RAPD) [2,173], and amplified fragment length polymorphism 
(AFLP) [2,174]. These methods have been largely replaced by PCR-based methods such as 
multilocus sequence typing (MLST) and multiple loci variable number tandem repeat analysis 
(MLVA) (175,176,177). While MLVA has greater discriminatory power than MLST [176], the 
latter method isunambiguous, reproducible and scalable for characterizing isolates of bacterial 
species using universally acceptable schema [178; https://pubmlst.org/). These attributes make 
MLST well-suited for epidemiological studies that span multiple research laboratories, and for 
comparing isolates over time [122,123,176,179]. 
Core genome MLST (cgMLST) is an extension of MLST, but provides higher resolution. 
Whereas a typical MLST scheme uses the alleles of seven house-keeping genes, cgMLST 
analyzes alleles from hundreds of genes, an approach facilitated by whole genome sequencing 
(WGS). cgMLST has been used for typing poultry mycoplasmas [125], investigating outbreaks 
of M. bovis in dairy cattle [111,180], and examining the genetic relatedness and evolution of 
isolates obtained from cattle in Denmark and neighbouring countries [181]. Authors of the 
Denmark study noted that cgMLST and WGS-typing techniques offered greater discriminatory 
power than MLST, and hence may become the new standard in phylogenetic typing. However, 
these methods do have disadvantages, namely cost, time, and the need for technical expertise for 
conducting the analyses and interpreting the results.  
A further progression into higher resolution strain typing involves genome-wide 
comparisons of single nucleotide variants (SNVs). This method can be applied to SNVs in the 





75 M. bovis isolates collected between 2006 and 2015 were of the same lineage, suggesting few, 
if any, incursions of new strains over the study duration. Similarly, an Israeli study used cgSNV 
to evaluate the genomic diversity of M. bovis isolates from mastitis cases between 1994 and 
2017, and compared these to BRD isolates from local feedlot cattle and from calves imported 
from Europe and Australia [182]. There was a clear genetic distinction between the isolates from 
Europe and Australia, with a dominant genotype associated with mastitis. wgSNV was also used 
to compare the relatedness of 250 M. bovis isolates originating from seven countries [183]. These 
isolates formed six clades, with USA isolates exhibiting the greatest genetic diversity and 
clustering with Canadian isolates.  
 The objective of this study was to assess the level of concordance between four different 
molecular genotyping methods (in silico MLST, cgMLST, cgSNV, wgSNV), using a dataset of 
129 M. bovis isolates. Secondly, to determine if one or more methods could resolve genotypic 
differences among isolates derived from cattle of varying health status (healthy, sick and dead 
cattle), from different anatomical locations (nasopharynx, lungs, and joints), different feedlots, 
and over a 12-year period (2006 to 2018).  
4.3 Materials and Methods 
4.3.1 Sample Collection 
A series of cross-sectional studies, spanning the years 2006 to 2018, provided 129 M. 
bovis isolates, which were recovered from the nasopharynges, lungs, and joints of feedlot cattle, 
as previously described [12]. Five of these isolates were recovered from cattle imported from 
Idaho, USA, while the rest originated in western Canada. All deep nasopharyngeal (DNP) swabs 
were obtained from healthy and morbid cattle. The animal’s health status was determined by the 
timing of the disease and presentation of clinical signs; BRD is the most common disease of 
feedlot cattle, with cases peaking within 21 days post-arrival to the feedlot. Thus, a putative BRD 
diagnosis was based upon the timing of disease, and a constellation of the clinical signs 
consistent with this disease (i.e. febrile, depressed, nasal discharge, dyspnea). Health status was 
determined by trained feedlot personnel. The DNP swabs from live cattle were obtained in 
accordance with Animal Use Protocols (#20070023; #20170021) approved by the University of 
Saskatchewan’s Animal Research Ethics Board and Lethbridge Research Center’s Animal Care 





examination from cattle having gross pathological findings consistent with a caseonecrotic 
bronchopneumonia and, in some instances, concurrent septic arthritis. 
4.3.2 Culture and isolation 
Small changes in media and isolation methods occurred over the 12-year period, with the 
2006 to 2008 isolates being cultured in Hayflick’s medium (prepared in-house) [184], and all 
subsequent isolates cultured with pleuropneumonia-like organism (PPLO) broth and agar (BD 
Difco, Fisher Scientific, Waltham, MA, USA). The PPLO media were supplemented with  10 g/L 
yeast extract (BD Diagnostic Systems, Fisher Scientific, Waltham, MA, USA) and 20% horse 
serum (Invitrogen, Fisher Scientific), as previously described [12]. Supplemented media also 
contained 0.05% thallium (I) acetate, 500 U/mL penicillin G, and/or 0.5% sodium pyruvate 
(Sigma-Aldrich, St. Louis, MO, USA). 
DNP samples and swabs of fresh cut tissues were used to inoculate PPLO starter cultures. 
Cultures were serial filtered through 0.45 and 0.20 µm filters (Basix, VWR International, 
Radnor, PA. USA) to remove other bacteria such as co-infecting BRD pathogens (0.45 µm) and 
select for Mycoplasma spp. (0.20 µm). Filtrates were inoculated into supplemented PPLO broth, 
and grown in a 5% CO2 atmosphere with 75% humidity at 37°C. Culture growth was visualized 
by agitating the culture tube to elicit a perceptible mass of organisms at the bottom of the tube. 
Cultures with visible growth were subcultured onto PPLO agar and incubated for 3 -6 days. 
Single colonies exhibiting a “fried-egg” morphology were picked and plated on PPLO agar, and 
incubated for 72 h. One to three individual colonies per culture were used to inoculate separate 
aliquots of PPLO broth. After 48 h, each culture was stored in PPLO with 20% (v/v) glycerol at -
80°C. A single culture was chosen to inoculate PPLO medium for DNA extraction. 
4.3.3 DNA extraction and identification 
Isolates were grown in PPLO medium for 48 h and genomic DNA extracted using the 
GenElute Bacterial Genomic DNA Kit (Sigma-Aldrich), per manufacturer’s instructions, with 
the exception that the final elution buffer was replaced with 10 mM Tris (pH 8.5). The extracted 
genomic DNA was assessed for quality using gel electrophoresis and quantified fluorometrically 
using a Qubit analyzer (Thermo Fisher Scientific, Waltham, MA, USA). The isolation of high 
molecular weight DNA with a yield ≥1 ng/µL was sufficient to proceed. Cultures were 





V4 16S rRNA gene [129]. The 16S rRNA amplicon was purified using a QIAquick PCR kit 
(Qiagen, Nevlo, Netherlands) and submitted for Sanger sequencing (Macrogen, Seoul, South 
Korea). Forward and reverse sequences were assembled and edited using the Staden Package 
(version 1.6-r, http://staden.sourceforge.net/), and compared to the National Center for 
Biotechnology Information (NCBI) nonredundant nucleotide database (nr) using BLASTn run 
with default settings; species was assigned based on the highest match identity [185]. 
4.3.4 Whole genome sequencing and assembly 
Sequencing libraries of genomic DNA were prepared using an Illumina Nextera XT DNA 
Library Preparation kit (Illumina Inc., San Diego, CA, USA), and sequenced on an Illumina 
MiSeq platform using the MiSeq v2 Reagent Kit to generate 250 bp paired-end reads. The raw 
paired-end reads are available from SRA under BioProject IDs PRJNA642970 and 
PRJNA708306. Genomes were assembled for the MLST, cgMLST, and cgSNV methods using 
Ridom SeqSphere+ in pipeline mode [186]. Raw paired-end reads were imported and 
preprocessed by down-sampling to 180X coverage and trimming at the 5’ and 3’ ends until an 
average quality of 30 in a window of 20 bases was achieved. Reads were assembled using 
SKESA [187]. Genome assembly for the wgSNV method was performed using Trimmomatic 
v0.39 [147] for read trimming and SPAdes v3.14.1 [188] for de novo assembly of the contigs. 
Trimmomatic was run with settings slidingwindow:5:15, leading:5, trailing:5, and minlen:25, 
and SPAdes was run with settings -careful and -k 127. Contigs with less than 1000 nucleotides 
were removed from the analysis. 
4.3.5 Genotyping methods 
De novo assemblies were used to assign allelic profiles and STs as per the PubMLST 
reference method (https://pubmlst.org/mbovis/). The M. bovis PG45 reference genome 
(NC_014760.1) was included in each genotyping method with the 129 isolates.  The MLST 
scheme included alleles of the following genes: dnaA, gltX, gpsA, gyrB, pta-2, tdk, and tkt [123; 
version update March 15, 2021).   
 The same de novo assemblies were used to develop an ad hoc cgMLST scheme using 
Ridom Seqsphere+ (version 6.0.2) [186]. The reference strain M. bovis PG45 (NC_014760.1) 
was used as the seed genome with the following criteria: minimum length of ≥50 bases; start and 





bp with identity ≥90%; and no overlap with genes of >4 bases. Genes identified in the seed 
genome were queried against the following ten penetration genomes to identify genes for 
inclusion in the final ad hoc cgMLST scheme: NC_015725.1, Hubei-1; NC_018077.1, HB0801; 
NZ_CP005933.1,  CQ-W70; NZ_CP011348.1, NM2012; NZ_CP007589.1, HB0801-P115; 
NZ_CP019639.1, 08M; NZ_CP023663.1, Ningxia-1; NZ_LT578453.1, JF4278; 
NZ_CP038861.1, 16M; and NZ_CP045797.1, XBY01. Penetration genomes were queried using 
BLAST (version 2.2.12) and required to have equivalent targets that met the BLAST hit overlap 
= 100% with identity of ≥90% in all query genomes. The following criteria were used: word size 
= 11; mismatch penalty = -1; match reward = 1; gap open costs = 5; and gap extension costs = 2. 
Targets were also required to have a single stop codon at the end of the gene in >80% of 
penetration query genomes. The resulting cgMLST scheme consisted of 506 genes (loci) and 
covered 55.1% of the M. bovis PG45 genome.  
The distance matrix used for cgMLST phylogenetic analysis omitted genomes missing 
>10% of distance columns and removed columns with missing values. This resulted in isolates 
being typed based on the alleles of 296 loci. 
SNVs for the cgSNV method were determined from 283 gene targets (loci) of the M. 
bovis PG45 reference genome (NC_014760). Comparing all genomes to these targets yielded 
6,408 SNV positions, which were filtered to 3,925 SNVs in 283 loci by only including 
substituted SNV positions (hide insertion/deletions), and having no neighbouring SNV positions 
in a window of ten bases. SNVs for the wgSNV method were identified within the 130 genomes 
by kSNP v3.1 [189], which yielded a SNV matrix file. The settings used for kSNP were -core 
and -k 31. The SNV matrix contained 14,383 SNVs across all genomes. 
Simpson’s diversity index [190] compared the discriminatory power of each strain typing 
method, based upon the clustering of isolates within the minimum spanning trees (MSTs) for the 
MLST, cgMLST, and cgSNV methods. The wgSNV method did not cluster any two of the 
isolates into a single type. Therefore, each isolate was classified as a unique type, as defined by a 
unique genotype for each isolate. 
4.3.6 Data presentation 
Neighbor joining (NJ) trees were created with iTOL [191] and the MSTs with Ridom 





Nei substitution model, using uniform rates and the nearest-neighbour-interchange heuristic 
method with MEGAX v10.1.1 [192]. The tree was visualized with iTOL and GrapeTree [193]. 
Isolates were grouped into clonal complexes (CCs) or clades (Cs), as appropriate. A CC was 
defined as a group of isolates with STs that differed by no more than two alleles from at least one 
other ST in the group. A singleton was a clonal group that differed from all other STs by at least 
three alleles. A clade was defined as a group of strains having a common biological ancestor. 
The CCs were assigned to MLST analyses, while clades comprised the MST of the cgMLST, 
cgSNV, and wgSNV analyses. These MSTs were determined by visual assignment based on the 
root of a tree or a ST central to the tree that served as a common ancestor.  
4.4 Results 
4.4.1 Isolates and assembly 
M. bovis isolates (n = 129), spanning 12 production years (2006-2018) and 21 feedlots 
(A-U), were recovered from 98 individual feedlot cattle (Appendix C). All 21 feedlots were 
located in western Canada; 45.0% (n = 58) of isolates originated from two feedlots (N, Q), each 
having a capacity of >20,000 head. Isolates were recovered from the nasopharynges (n = 49), 
lungs (n = 45), and joints (n = 35). Most isolates were derived from dead (n = 82) versus healthy 
(n = 32) or diseased (n = 15) cattle. DNP swabs (n = 49) were obtained from healthy (n = 32), 
diseased (n = 15), and dead (n = 2) animals. All isolates (n = 129) underwent WGS and de novo 
assembly: mean N50 = 18,448 (range 997-32908), contig count = 186 (range 79-797), coverage 
= 84 (range 12-177), and approximate completed genome size = 90% (60-100%) relative to the 
PG45 reference genome. 
4.4.2 MLST 
A total of 126 of 130 genomes (129 isolates plus PG45 reference genome) were assigned 
an existing ST. Four isolates could not be typed due to missing allele(s) and are designated as ST 
‘Unknown’ (one also had a novel allele at the pta2 locus), a reflection of their low-quality 
assemblies (N50: 997-2,494; contig count: >500; coverage: 12-51, approximate genome size: 
≤80%). The MLST scheme typed the 125 isolates into 24 known STs, and six newly identified 
STs (ST149 to ST154) (Table 4.1). The PG45 reference genome included in the analysis was 
assigned ST12, as expected. Simpson’s diversity index was 0.932, indicating reasonably strong 





[188] had differing MLST STs than those assigned by SKESA [187] and Ridom SeqSphere+. 
Two of these were within the set of four isolates that had missing alleles. These differences are 
likely due to low quality sequencing of these isolates and the use of alternate assembly processes.  
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Table 4.1 Number of MLST sequence types (STs) of Mycoplasma bovis isolates (n = 125) by 
production year (2006 – 2018) and health status (healthy, diseased and dead). Total represents 





Production Year Health Status 
Total 
2006 2007 2008 2014 2015 2016 2017 2018 Healthy Diseased Dead 
2  2    1    1 2 3 
14       1  1   1 
21 1 4     2  2 3 2 7 
24  12   1    5 6 2 13 
27        3   3 3 
40  5       3 2  5 
42 3 2  1 1    3 2 2 7 
43        1 1   1 
44       9    9 9 
45       3 2 4  1 5 
48  1       1   1 
52  1    3     4 4 
60    1  13 1 8   23 23 
61      1     1 1 
62  1       1   1 
65      6 1  1  6 7 
66       2  2   2 
67       12    12 12 
70  1   2     1 2 3 
75   1        1 1 
76    2       2 2 
77      2     2 2 
79      1     1 1 
80      3     3 3 
149        1   1 1 
150        1 1   1 
151 1        1   1 
152       1  1   1 
153        2 2   2 
154       2  2   2 
Total 5 29 1 4 4 30 34 18 31 15 79 125 
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The most prevalent STs were ST60 (23/130 or 17.69%), ST24 (13/130 or 10.00%), and 
ST67 (12/130 or 9.23%), which is much higher than what is reported in the PubMLST database 
(accessed 12 March, 2021): ST60 (12/1,139 or 1.05%), ST24 (9/1,139 or 0.79%) and ST67 
(9/1,139 or 0.79%). Of the ST60 isolates, 12 of 23 had been used in another unrelated study 
[123], and are represented in the PubMLST database, but under isolate identifiers (see Appendix 
C). The STs with the highest frequency in the PubMLST database were ST52 (127/1,139 or 
11.15%), ST62 (71/1,139 or 6.23%) and ST21 (31/1,139 or 2.72%), all of which are frequently 
identified in North America, but were infrequent in the current study. 
Isolates (n = 35) recovered from feedlot N, between the years 2016 to 2018, represented 
nine STs, with ST60 (n = 10; 28.6%) being the most prevalent in all years. The 22 isolates 
recovered from feedlot Q in 2007 were categorized into six STs, 12 (54.5%) being ST24. Two 
STs (ST2 and ST21) were of particular interest because they were separated in time and space. 
ST2 was isolated from feedlot Q in 2007 and from N in 2016, while ST21 was recovered from 
feedlot Q in 2007 and from feedlot N in 2017. These feedlots were separated by a distance of 
approximately 500 km. Five isolates were derived from cattle imported from the northern United 
States. 
Isolates clustered into two clonal complexes (CC1, CC2) and as four singletons including 
the PG45 reference strain (ST12, ST42, ST43, ST75) (Figure 4.1). The ST52 and ST60 isolates 
formed the foci of the CCs in the MLST minimum spanning tree (Figure 4.2). Two isolates 
(MPLM0830, MPLM0608) from 2018 had allelic combinations that had not been previously 
described. Five STs persisted within the western Canadian cattle population for many years: ST2 
(2007-2016), ST21 (2006-2017), ST24 (2007-2015), ST42 (2006-2015), and ST70 (2007-2015). 
Three of these STs (ST2, ST21, ST24) were grouped in CC2, whereas ST70 was grouped with 
CC1 and ST42 was a singleton. 
The dataset included 31 pairs of lung-joint samples obtained from individual animals, 
with 28 lung-joint pairs having both isolates successfully typed using MLST. In 18 (64.3%) 








Figure 4.1 MLST neighbor joining tree of 126 Mycoplasma bovis isolates typed by MLST. 
Starting from the innermost ring, the rings contain information on isolate identifiers, MLST 
sequence type (ST), production year, feedlot (A-U), the anatomical sampling location, and health 
status at sampling. Two clonal complexes are depicted with red (CC1) and blue (CC2) branch 







Figure 4.2 Minimum spanning tree of 126 Mycoplasma bovis genomes (125 field isolates plus 
PG45) typed by MLST. Clonal complexes 1 and 2 are surrounded by red and blue lines, 
respectively. Sequence types are colour coded with the size of the circle reflecting the number of 
isolates, with the partitioning lines within a circle delineating isolates with an identical genotype. 
The number of different alleles is indicated over the line connecting the sequence types. The 
PG45 reference genome is identified as the singleton with ST12.
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4.4.3 cgMLST and cgSNV analyses 
A total of 102 genomes (101 isolates and PG45) were typed by the cgMLST (Figure 4.3, 
Figure 4.4) and cgSNV (Figure 4.5, Figure 4.6) methods. Figures 4.4 and 4.6 provide the MSTs 
of the isolates, with three clades (C1, C2, C3) branching from a single focus consisting of an 
isolate with MLST ST62. Isolates from these clades tended to cluster together in the neighbour 
joining (NJ) tree, but small subclades (Figures 4.3 and 4.5) branched from the root and contained 
isolate specific clades with the MSTs. Both cg analyses grouped the five STs previously 
discussed (ST2, ST21, ST24, ST42, ST70) into two clades, with ST2, ST21, ST24, and ST42 
grouped in C3, and ST70 allocated to C2 (Figures 4.4 and 4.6). Although there were minor 
differences observed in overall clade membership between the MLST and the two cg methods, 
results were fairly consistent. Simpson’s diversity index was 0.987 for cgMLST and 0.984 for 
cgSNV, indicative of strong separation of the isolates into individual STs, with most isolates 






Figure 4.3 cgMLST neighbor joining tree of 102 Mycoplasma bovis genomes based on alleles at 
296 core genome loci. Starting from the innermost ring, the rings contain information on isolate 
identifiers, MLST sequence type (ST), production year, feedlot (A-U), anatomical sampling 
location and animal health status at sampling. The branches are coloured in accordance with the 
three clades (C1, red; C2, blue; C3, green) identified in Figure 4.4, highlighting the differences 









Figure 4.4 Minimum spanning tree of 102 Mycoplasma bovis isolates (101 field isolates plus 
PG45) created with cgMLST, based on alleles at 296 core genome loci. Clades 1 - 3 are denoted 
by a surrounding circle. The isolates are identified by MLST sequence type and production year 
(ST, Production Year).  Sequence types are colour coded with the size of the circle reflecting the 
number of isolates, with the partitioning lines within a circle delineating isolates with an 








Figure 4.5 cgSNV neighbor joining tree of 102 Mycoplasma bovis isolates based on 283 core 
genome loci (3,925 SNVs).  Starting from the innermost ring, the rings contain information on 
isolate identifiers, MLST sequence type (ST), production year, feedlot (A-U), anatomical 
sampling location, and health status at sampling. The branches are coloured to match the clades 
(C1, red; C2, blue; C3, green) identified in Figure 4.6, highlighting the differences between the 








Figure 4.6 Minimum spanning tree of 102 Mycoplasma bovis isolates (101 field isolates plus 
PG45) based on 283 core genome loci, using cgSNV, based on 3,925 SNVs. The clades are 
indicated by an encompassing circle. The 102 M. bovis isolates are identified by MLST sequence 
type and production year (ST, Production Year). The nodes are colour coded by the MLST 
sequence type. The size of the circle reflects the number of isolates represented, with the 
partitioning lines within a circle delineating isolates with an identical genotype. The number of 






All 130 genomes were typed by wgSNV and no two isolates shared an identical SNV 
matrix, hence each isolate was unique (Figure 4.7, Figure 4.8). As a result, Simpson’s diversity 
index was 1.000. Two primary clades (C1, C2) branched into two sub-clades of approximately 
equal size. A single isolate (ST62) was positioned evenly between the two clades. wgSNV was 
able to resolve isolates with the same MLST ST assignment compared to the cgMLST and 
cgSNV methods. Similar to cgMLST and cgSNV, wgSNV grouped ST2, ST21, ST24, ST42 into 








Figure 4.7 wgSNV maximum-likelihood tree of 130 Mycoplasma bovis genomes based on 
14383 SNVs in the core and accessory genomes. Starting from the innermost ring, the rings 
contain information on isolate identifiers, MLST sequence type (ST), production year, feedlot 
(A-U), anatomical sampling location, and health status at sampling. Clades 1 and 2 are indicated 
by blue and red, respectively. Isolate MPLM0703 (ST62) falls evenly between both clades and as 








Figure 4.8 Maximum-likelihood tree of 130 Mycoplasma bovis isolates (129 field isolates plus 
PG45) based on 14383 SNVs in the core and accessory genomes typed by wgSNV. Clades 1 and 
2 are indicated by a surrounding line in red and blue, respectively. The isolates are labelled with 
MLST sequence type and production year (ST, Production Year), and colour coded with MLST 






4.5 Discussion and Conclusion 
This is the first study to compare four different phylogenetic typing methods using a 
relatively large and diverse set of M. bovis isolates derived from western Canadian feedlot cattle. 
Overall, a greater number of genomes were typed using the MLST scheme (n = 126) compared 
to the cgMLST or cgSNV methods (n = 102), which required assembly of hundreds of loci 
constituting a large portion of the genome. The wgSNV method successfully typed all 130 
genomes, highlighting the robustness of the SPAdes and kSNP software, even with inputs of 
variable sequencing depth. All four methods had a high degree of discriminatory power, as 
judged by Simpson’s diversity index. MLST had the lowest discriminatory power, while 
cgMLST had a modestly higher index than cgSNV. Despite some differences in the phylogenetic 
outputs of the four methods, the MLST method generated a pattern of clonal complexes (CC) 
comparable to the clades generated from the cgMLST, cgSNV and wgSNV methods. This is 
noteworthy since the MLST scheme relied on seven housekeeping genes, representing <1% of 
the M. bovis PG45 reference genome. In contrast, the cgMLST scheme was derived from 506 
loci, covering approximately 55% of the genome. The cgSNV method analyzed 3,925 SNVs 
from 283 loci, while the wgSNV matrix utilized 14,383 SNVs, generating the highest genotypic 
resolution.  
Since core genome and whole genome methods are based on a larger representation of 
the genome, theoretically they should have a greater potential to resolve relationships than the 
seven-loci MLST scheme. This makes the cgMLST, cgSNV, and wgSNV method ideally suited 
for epidemiological investigations where small variations between STs may be consequential. 
Parker et al. [103] applied wgSNV analysis to Australian M. bovis (n = 75) isolates and found a 
very high level of homogeneity among isolates; the maximum number of single nucleotide 
polymorphisms (SNPs) between any two isolates was 50 [103]. This level of resolution led the 
researchers to conclude that a single strain of M. bovis was circulating within Australia’s cattle 
population. This is quite unique, since a number of other country-level studies have found 
multiple clusters of genetically distant M. bovis STs within the population of cattle 
[181,182,183,194]. Furthermore, these studies provided some insight into the movement of 
specific STs from country to country, and overtime. These higher resolution methods have also 





within the same dairy farm [180], and the introduction of M. bovis into dairy herds via 
contaminated semen [111].  
The higher concordance and resolution of the cgMLST, cgSNV, and wgSNV methods 
was evident when focusing on five STs (ST2, ST21, ST24, ST42, ST70), representing 33 isolates 
obtained between 2006 to 2017. The MLST scheme grouped three STs (ST2, ST21, ST24) to 
clonal complex 2 (CC2); ST70 to CC1; and ST42 as a singleton. Whereas both the cgMLST and 
cgSNV analyses assigned four STs (ST2, ST21, ST24, ST42) to clade 3 (C3), and ST70 to C2. 
The wgSNV analysis yielded results that were similar to the cgMLST and cgSNV methods. 
These findings underscore that all four methods had similar assignments for four of the five STs. 
However, because ST42 was a triple locus variant, it became an outlier or singleton. As the 
cgMLST, cgSNV and wgSNV methods utilize hundreds to thousands of discrete data points to 
compare the genetic relatedness of isolates, it grouped ST42 alongside other STs into a clade.  
The MLST method identified 30 different STs, which underscores the genetic diversity of 
M. bovis in western Canada. This is most likely related to the underlying structure of the 
Canadian cattle industry and how feedlot cattle are procured. At the time of the last agricultural 
census (2016), Canada had approximately 54,000 beef cattle farms, with 38,700 (72%) located in 
western Canada (https://www150.statcan.gc.ca/n1/en/type/data?text=40221). Some western 
Canadian feedlots also import cattle from the United States. Since most feeder cattle are sold at 
auction, extensive commingling of cattle from multiple owners occurs during procurement. Once 
sold, the cattle are assembled, transported, and then processed and further commingled at the 
feedlot. This is also occurring in the autumn months, when inclement weather conditions arise. 
Conceivably, commingling, transport, and changing environmental conditions all contribute to 
stress, which facilitates increased shedding from carrier animals [170]. Thus, given the broad 
catchment from which cattle are sourced and mixed, it is understandable that feedlots had 
multiple STs circulating during the same time period. Interestingly, ST2 was isolated from two 
feedlots in 2007 (feedlots Q and K), and then not until nine years later from feedlot N. Similarly, 
ST21 was isolated from feedlots J in 2006, Q in 2007, and then from feedlot N and O in 2017. 
Not only were these isolates separated in time, but feedlots N and Q were geographically located 
approximately 500 km apart. This separation by time and space suggests that some STs may be 





While Canada’s feedlot sector is concentrated in Alberta, there is bilateral trade in cattle 
between Canada and the United States, which is noteworthy because five isolates from the 
American cattle were evenly distributed amongst the Canadian isolates within the NJ trees and 
MSTs (identified in Appendix C). These results support the findings of a recent study wherein 
wgSNV analysis found a high degree of genetic diversity within the American isolates, with 
Canadian isolates clustering within the same clade as the American isolates [192].  
There were 30 MLST STs dispersed over 12 production years, with two strains (ST21, 
ST52) having been reported in bovine isolates outside of North America: ST21 reported in 
Europe and Asia, whereas ST52 was reported in Europe, Asia, and Oceania (PubMLST isolate 
database accessed 12 March, 2021). ST21 is of particular interest in that it has a worldwide 
distribution, and a recent European study found it to be a common ancestor to isolates recovered 
after 2010. This worldwide distribution underscores the international trade in cattle, and the need 
for biosecurity measures to mitigate the transmission of M. bovis and other potential production-
limiting pathogens. It is also noteworthy that ST21 has also been isolated from bison (PubMLST 
isolate database accessed 12 March, 2021). 
WGS allows typing by multiple methods to be done in silico, with Ridom Seqsphere+ 
making higher resolution typing methods more accessible compared to the knowledge required 
to construct a customized whole genomic analysis pipeline. Established typing methods, such as 
MLST will invariably continue to support in silico efforts to conduct comparative studies using 
historical and contemporary data. WGS of isolates, particularly when analyzing with Ridom 
Seqsphere+ provides the opportunity to merge established methods (MLST) with more robust 
core genome approaches (i.e. cgMLST and cgSNV). Additionally, given that the cost of WGS is 
comparable to the sequencing of seven PCR amplicons, particularly for a small 1-Mbp genome 
like M. bovis, WGS is likely to become the standard for detailed phylogenetic studies. The ability 
to cost-effectively generate high quality M. bovis assemblies from long reads will enable greater 
use of cgMLST, cgSNV, and wgSNV phylogenetic typing methods [195]. 
 A caveat for using the cg methods is the need for greater sequencing depth and fewer 
sequencing artifacts in order to generate more complete, higher quality assemblies. This was 
evident from the fact that more isolates were typed by MLST than cgMLST or cgSNV, while the 





better able to process poorer quality sequencing data because it analyzes the entire genome to a 
greater degree than the other methods. However, it is not without its faults. It is possible that the 
assembly software may have erroneously assembled the small subsets of the genome resulting in 
false SNPs contributing to the uniqueness of the genotypes. However, misassembles occur only 
infrequently and in sections of an assembly with poor coverage, making this occurrence in our 
dataset unlikely. Care must also be taken when choosing analysis software, and associated input 
parameters. This is exemplified in the NJ trees MSTs, which were similar trees, but with 
differences in the position of ST2, ST40, ST44, ST45, and ST75 within the trees. This highlights 
the need for high quality sequence data as the analysis moves from MLST to more complex 
methods such as cgSNV or wgSNV.  
The study design was appropriate for comparing the four genotyping methods. However, 
it was equivocal as to whether the lack of association between genotypes (STs) and phenotypes 
(year, health status, anatomical location) was real, or was related to the limited number of 
isolates collected. Obtaining a complete set of DNP swabs, lung, and joint samples from each 
animal would have helped in determining whether STs exhibited a tropism for specific tissues. 
On this point, it was salient that the dataset included paired lung-joint samples from 28 animals, 
18 (64.3%) of which had the same ST in the lung and joint, suggesting the absence of a single 
tissue tropism. However, in ten cases, the genotype of lung and joint isolates within the same 
animal differed, underscoring the need for polyvalent vaccines. Others have also suggested that a 
polyvalent vaccine maybe required to cover the broad functional diversity found amongst 
isolates [192]. 
The lack of association between genotype and phenotype is certainly not unique, but 
rather is the emerging consensus. A number of studies using higher resolution typing methods 
have been unable to show linkages between clusters and anatomical sample locations [103,194] 
or to health status [103,182]. However, one of the issues is that these studies have not been 
specifically designed to investigate these associations. This is problematic as the lack of 
association may be related to not only an inadequate number of samples, but an unbalanced study 
design. Many of the studies have biases in sampling related to year, anatomical location, 
geographical location and health status. These confounding factors may result in type I and II 





status in feedlot cattle. Animals deemed healthy on-arrival and at the time of sampling, may 
develop BRD within days. Conversely, BRD is a polymicrobial disease, and hence clinical 
disease does not always equate to mycoplasmosis. This conundrum is best addressed by 
comparing isolates from healthy animals to those obtained at the time of postmortem 
examination from tissues (lungs and joints) exhibiting a pathology consistent with 
mycoplasmosis. 
 Each genotyping method has strengths and weaknesses depending on the research 
question. MLST is best suited as an initial screening method for detecting the presence of 
genetically distinct strains, and is amenable to both PCR and in silico methods. Furthermore, the 
M. bovis PubMLST database is curated and accessible through a publicly available website. 
While cgMLST, cgSNV and wgSNV analyses allow for typing of strains, they also provide a 
higher level of genetic resolution, which may be used to discern clinically relevant differences 
such as tissue tropisms, antimicrobial resistance, or virulence 
The wgSNV method successfully typed all 129 field isolates, whereas the cg methods 
only typed 101 isolates, an outcome that may be rectified with greater sequencing depth. Overall, 
clade membership between the MLST and higher resolution methods was similar on visual 
assessment of the NJ trees and MSTs, with cgMLST and cgSNV having the highest degree of 
concordance. The wgSNV provided an incrementally higher level of genomic resolution and 
detail, which may have utility in some epidemiological investigations and for addressing 
research questions relating to gene function and characterization. Although the wgSNV method 
was very powerful and robust, it is less user-friendly, requiring specialized training in 
bioinformatics. Conversely, the cg analyses were performed using Ridom SeqSphere+, which is 
graphical interface software that non-bioinformaticians can use with moderate background 
knowledge. Thus, it provides greater resolution than MLST and requires less specialized 
training, but it is relatively expensive, particularly if only being used on a limited number of 
isolates. None of the methods could show a clear association between genotype and phenotype, 
which may reflect the limitations of these methods, or it could be related to a relatively small 






5 GENERAL SUMMARY AND CONCLUSION 
5.1 Discussion 
The overall elevated level of antimicrobial resistance in Mycoplasma bovis reported in 
this study is consistent with trends reported in other Canadian studies [10-13] and worldwide 
[14- 22]. An average administration of 3 different antimicrobial classes to feedlot cattle at the 
time of death was also comparable to the two classes reported by another Canadian study [11]. 
Isolates in the current study were largely resistant to all macrolides assessed (gamithromycin, 
tilmicosin, tildipirosin, tylosin, and tulathromycin), which was not unexpected given their 
metaphylactic administration for BRD in western Canadian feedlot cattle [44]. The predominate 
susceptibility to florfenicol is encouraging, as it is classified as a lower category III (medium 
importance) antimicrobial by Health Canada [55]. However, macrolides are classified as a higher 
category II (high importance) antimicrobial. The elevated level of macrolide resistance 
underscores the global issue with antimicrobial and reinforces the importance in surveillance of 
antimicrobial resistance and the appropriate usage of antimicrobials to reduce the selection 
pressure of resistance and maintain their utility. 
In the absence of a standardized AST protocol and established clinical breakpoints for M. 
bovis by Clinical and Laboratory Standard Institute (CLSI) or the European Committee on 
Antimicrobial Susceptibility Testing (EUCAST), interpretation of MIC values and comparison 
of AST results between studies can be difficult if not impossible. This, combined with the 
fastidious nature of culturing M. bovis, makes querying the genotype to determine AMR more 
amenable to expeditious assessment of AST than culture dependent methods, a facet of 
antimicrobial stewardship. When investigating the genotypic basis for macrolide resistance in 
chapter 3, isolates with mutations in both domain II and V of 23S rRNA gene alleles correlated 
with macrolide resistance in all 5 macrolides tested, however nearly all isolates were resistant to 
tildipirosin and tilmicosin regardless of genotype. Resistance was also observed in isolates with 
mutations in domain II and L4 and L22 ribosomal proteins, with the exception of tulathromycin. 
These findings highlight the utility of assessing antimicrobial susceptibility based on the 
genotypic composition of M. bovis. Genotypic assessment of antimicrobial susceptibility of M. 
bovis would aid in surveillance of antimicrobial susceptibility in a more cost effective and 





Through phylogenetic analysis of M. bovis isolates in chapter 4, the genetic diversity of 
M. bovis isolates in western Canada was underscored by identification of 30 STs in 125 isolates. 
This finding was not entirely surprising given the movement and commingling of cattle during 
transport and at auction-marts prior to arrival at the feedlot. Interestingly, two MLST strain types 
(ST 2 and 21) were found separated in both time and space, suggesting dominance of certain 
strain types. Type STs (ST21 and ST 52), had also been reported in isolates derived from cattle 
outside of North America. Unfortunately, none of the different in silico typing methods were 
able to correlate genotype to phenotype, which was consistent with findings in other studies 
[103,182,194]. However, the phylogenetic relationship of the isolates using each of the four 
methods were comparable with resolution increasing with complexity of analysis.  
Limitations of the studies included unequal representation of isolates over production 
years. Unequal representation of production years could be due in part to the expense and 
extensive time associated with sampling of cattle and culturing of M. bovis. Furthermore, M. 
bovis-associated disease is seasonal as it largely occurs weeks to months following fall entry of 
cattle into feedlots, limiting when sampling is likely to yield M. bovis. Due to this, there was a 
sampling bias towards dead cattle that had received antimicrobials prior to death in an effort to 
isolate M. bovis. In chapter 3, there was a low number (n = 2) of isolates with a wildtype 23S 
rRNA genotype to serves as the basis of comparison for macrolide resistance and in chapter 4 the 
inability to discern a clear association between genotype and phenotype could be due to method 
selection, small sample size, or the fact that isolates predominately came from cattle that had 
died from M. bovis related disease. 
Overall, assessment of antimicrobial susceptibility via a genotypic approach is highly 
amenable to M. bovis specifically given the requirement for specialized conditions and laborious 
nature of culturing M. bovis in vitro. Furthermore, given the increased level of AMR in M. bovis 
in western Canadian feedlot cattle warranting routine surveillance, a more rapid assessment of 
AMR utilizing a genotypic approach could become incorporated in a feedlot production setting 
in the future. This would not necessarily be directly done by the producer, but rather 
incorporated as part of the development and review of antimicrobial use protocols put into place 





5.2 Future Research 
The development of a collection of isolates with paired antimicrobial susceptibility data 
and WGS for this study provides an opportunity to bioinformatically interrogate the M. bovis 
genome to potentially elucidate new information regarding mechanisms of antimicrobial 
resistance and virulence without the requirement for additional sample collection and processing. 
Given the limitation of the current and previous studies [103,182,194] to definitively determine 
whether there was an association between genotype and tissue tropism or health status, a study 
could be designed to investigate those relationship specifically. This could potentially be applied 
to assess whether strain types (eg. MLST STs) can act as a proxies for clinically relevant 
parameters such and antimicrobial resistance or virulence. Furthermore, given the successful 
correlation between macrolide resistance and phenotype, there could be utility in developing a 
robust PCR based assay to assess antimicrobial resistance of M. bovis from a single nasal swab, 
despite the mixed population of microbes associated with BRD. 
5.3 Conclusion 
In conclusion, AMR was observed to macrolides and antimicrobials in general, with 
isolates remaining predominately susceptible to a single antimicrobial (florfenicol). This 
suggests that AMU practices should not necessarily focus on how best to apply florfenicol to 
current antimicrobial use strategies, but rather how current practices could be adapted to best 
preserve its utility otherwise its utility could be lost. Given the fastidious nature of culturing M. 
bovis and the need for expeditious antimicrobial susceptibility information, assessing 
antimicrobial resistance of M. bovis genotypically was shown to be highly comparable to 
phenotypic (AST) data. Given the increasing global concern of M. bovis, implementation of 
strain typing will become increasingly important in the surveillance of M. bovis. However, 
appropriate selection of the strain typing method is contingent on the end application, as pros and 
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APPENDIX A – CHAPTER 2: MYCOPLASMA BOVIS ISOLATES 
Table A2.1. Summary of mycoplasma isolates discussed in Chapter 2. Isolates were derived 
from different anatomical locations (nasopharynx, lung, joint) from cattle with different health 
statuses (healthy, disease, dead) collected from feedlots A to Z from 2006 to 2018. The cattle 
identifier associated with each isolate is indicated, as more than one isolate was derived from a 












MP0064 2014 Y lung dead C073 
MP0209 2014 I joint dead C056 
MP0219 2014 I lung dead C056 
MPLM0636 2014 S lung dead C074 
MYCO062 2014 Z lung dead C065 
MYCO066 2014 W lung dead C067 
MYCO076 2014 Z lung dead C066 
MYCO081 2014 X joint dead C070 
MYCO096 2014 W lung dead C068 
MP0057 2015 X lung dead C069 
MP0058 2015 I lung dead C058 
MP0063 2015 I lung dead C059 
MP0070 2015 Z lung dead C064 
MP0071 2015 I lung dead C060 
MP0073 2015 I lung dead C061 
MP0075 2015 V lung dead C071 
MP0077 2015 I lung dead C062 
MP0079 2015 I lung dead C055 
MP0183 2015 I joint dead C063 
MPLM0637 2015 I lung dead C057 





MPLM0003 2016 F lung dead C072 
MPLM0004 2016 F joint dead C072 
MPLM0007 2016 T lung dead C045 
MPLM0008 2016 T joint dead C045 
MPLM0009 2016 T lung dead C046 
MPLM0010 2016 T joint dead C046 
MPLM0011 2016 T lung dead C047 
MPLM0012 2016 T joint dead C047 
MPLM0013 2016 T lung dead C048 
MPLM0014 2016 T joint dead C048 
MPLM0015 2016 T lung dead C049 
MPLM0016 2016 T joint dead C049 
MPLM0017 2016 T lung dead C050 
MPLM0018 2016 T joint dead C050 
MPLM0019 2016 T lung dead C051 
MPLM0020 2016 T joint dead C051 
MPLM0025 2016 T lung dead C052 
MPLM0026 2016 T joint dead C052 
MPLM0029 2016 N lung dead C001 
MPLM0030 2016 N joint dead C001 
MPLM0031 2016 T lung dead C053 
MPLM0033 2016 N lung dead C022 
MPLM0034 2016 N joint dead C022 
MPLM0035 2016 T lung dead C054 
MPLM0036 2016 T joint dead C054 
MPLM0037 2016 T lung dead C043 
MPLM0039 2016 T lung dead C044 
MPLM0040 2016 T joint dead C044 
MPLM0041 2016 N lung dead C002 





MPLM0064 2017 N joint dead C023 
MPLM0066 2017 N lung dead C024 
MPLM0067 2017 N joint dead C024 
MPLM0069 2017 N lung dead C025 
MPLM0070 2017 N joint dead C025 
MPLM0073 2017 N joint dead C026 
MPLM0084 2017 N lung dead C027 
MPLM0085 2017 N joint dead C027 
MPLM0087 2017 N lung dead C003 
MPLM0088 2017 N joint dead C003 
MPLM0090 2017 N lung dead C028 
MPLM0091 2017 N joint dead C028 
MPLM0093 2017 N lung dead C004 
MPLM0094 2017 N joint dead C004 
MPLM0102 2017 N lung dead C005 
MPLM0103 2017 N joint dead C005 
MPLM0105 2017 N lung dead C006 
MPLM0106 2017 N joint dead C006 
MPLM0108 2017 N lung dead C029 
MPLM0111 2017 N lung dead C007 
MPLM0112 2017 N joint dead C007 
MPLM0114 2017 N lung dead C008 
MPLM0143 2017 N joint dead C030 
MPLM0145 2017 N lung dead C009 
MPLM0146 2017 N joint dead C009 
MPLM0148 2017 N lung dead C010 
MPLM0149 2017 N joint dead C010 
MPLM0154 2017 N lung dead C011 
MPLM0155 2017 N joint dead C011 





MPLM0158 2017 N joint dead C012 
MPLM0160 2017 N lung dead C013 
MPLM0164 2017 N joint dead C014 
MPLM0533 2018 N lung dead C015 
MPLM0534 2018 N joint dead C015 
MPLM0535 2018 N nasopharynx dead C015 
MPLM0537 2018 N lung dead C016 
MPLM0538 2018 N joint dead C016 
MPLM0539 2018 N nasopharynx dead C016 
MPLM0541 2018 N lung dead C017 
MPLM0542 2018 N joint dead C017 
MPLM0543 2018 N nasopharynx dead C017 
MPLM0545 2018 N lung dead C018 
MPLM0546 2018 N joint dead C018 
MPLM0547 2018 N nasopharynx dead C018 
MPLM0549 2018 N lung dead C031 
MPLM0552 2018 N lung dead C032 
MPLM0553 2018 N nasopharynx dead C032 
MPLM0555 2018 N lung dead C019 
MPLM0556 2018 N joint dead C019 
MPLM0559 2018 N lung dead C020 
MPLM0560 2018 N joint dead C020 
MPLM0566 2018 N lung dead C033 
MPLM0567 2018 N nasopharynx dead C033 
MPLM0569 2018 N lung dead C034 
MPLM0578 2018 N lung dead C035 
MPLM0579 2018 N nasopharynx dead C035 
MPLM0582 2018 N nasopharynx dead C036 
MPLM0584 2018 N lung dead C037 





MPLM0588 2018 N nasopharynx dead C038 
MPLM0593 2018 N lung dead C039 
MPLM0608 2018 N lung dead C021 
MPLM0609 2018 N nasopharynx dead C021 
MPLM0611 2018 N lung dead C040 
MPLM0622 2018 N nasopharynx dead C041 
MPLM0624 2018 N lung dead C042 






















APPENDIX B – CHAPTER 3: MYCOPLASMA BOVIS ISOLATES 
Table A3.1. Summary of mycoplasma isolates discussed in Chapter 3. Isolates were derived 
from different anatomical locations (nasopharynx, lung, joint) from cattle with different health 
statuses (healthy, disease, dead) collected from feedlots A to Z from 2006 to 2018. The cattle 
identifier associated with each isolate is indicated, as more than one isolate was derived from a 












MPLM0640 2006 G nasopharynx healthy C091 
MPLM0643 2006 G nasopharynx healthy C092 
MPLM0648 2006 J nasopharynx diseased C094 
MPLM0649 2006 P nasopharynx diseased C102 
MPLM0642 2006 U nasopharynx diseased C134 
MPLM0632 2007 K nasopharynx dead C096 
MPLM0631 2007 L joint dead C097 
MPLM0629 2007 Q nasopharynx diseased C103 
MPLM0644 2007 Q nasopharynx diseased C104 
MPLM0645 2007 Q nasopharynx diseased C105 
MPLM0647 2007 Q nasopharynx diseased C106 
MPLM0652 2007 Q nasopharynx diseased C107 
MPLM0657 2007 Q nasopharynx diseased C108 
MPLM0660 2007 Q nasopharynx diseased C109 
MPLM0661 2007 Q nasopharynx diseased C110 
MPLM0662 2007 Q nasopharynx diseased C111 
MPLM0664 2007 Q nasopharynx diseased C112 
MPLM0665 2007 Q nasopharynx diseased C113 
MPLM0666 2007 Q nasopharynx diseased C114 
MPLM0669 2007 Q nasopharynx dead C115 





MPLM0692 2007 Q nasopharynx healthy C117 
MPLM0698 2007 Q nasopharynx healthy C118 
MPLM0700 2007 Q nasopharynx healthy C119 
MPLM0703 2007 Q nasopharynx healthy C120 
MPLM0706 2007 Q nasopharynx healthy C121 
MPLM0713 2007 Q nasopharynx healthy C122 
MPLM0714 2007 Q nasopharynx healthy C123 
MPLM0715 2007 Q nasopharynx healthy C124 
MPLM0646 2007 R nasopharynx healthy C125 
MPLM0667 2007 R nasopharynx healthy C126 
MPLM0668 2007 R nasopharynx healthy C127 
MPLM0670 2007 R nasopharynx healthy C128 
MPLM0671 2007 R nasopharynx healthy C129 
MPLM0630 2008 K joint dead C095 
MP0209 2014 I joint dead C056 
MPLM0635 2014 H lung dead C093 
MP0219 2014 I lung dead C056 
MPLM0636 2014 S lung dead C074 
MPLM0634 2015 M lung dead C098 
MP0079 2015 I lung dead C055 
MPLM0637 2015 I lung dead C057 
MPLM0638 2015 I joint dead C055 
MPLM0003 2016 F lung dead C072 
MPLM0004 2016 F joint dead C072 
MPLM0007 2016 T lung dead C045 
MPLM0008 2016 T joint dead C045 
MPLM0009 2016 T lung dead C046 
MPLM0010 2016 T joint dead C046 
MPLM0011 2016 T lung dead C047 





MPLM0013 2016 T lung dead C048 
MPLM0014 2016 T joint dead C048 
MPLM0015 2016 T lung dead C049 
MPLM0016 2016 T joint dead C049 
MPLM0017 2016 T lung dead C050 
MPLM0018 2016 T joint dead C050 
MPLM0020 2016 T joint dead C051 
MPLM0025 2016 T lung dead C052 
MPLM0026 2016 T joint dead C052 
MPLM0029 2016 N lung dead C001 
MPLM0030 2016 N joint dead C001 
MPLM0031 2016 T lung dead C053 
MPLM0035 2016 T lung dead C054 
MPLM0036 2016 T joint dead C054 
MPLM0037 2016 T lung dead C043 
MPLM0039 2016 T lung dead C044 
MPLM0041 2016 N lung dead C002 
MPLM0042 2016 N joint dead C002 
MPLM0132 2016 S lung dead C130 
MPLM0134 2016 S lung dead C131 
MPLM0135 2016 S joint dead C131 
MPLM0021 2016 T lung dead C133 
MPLM0022 2016 T joint dead C133 
MPLM0815 2017 A nasopharynx healthy C075 
MPLM0820 2017 A nasopharynx healthy C077 
MPLM0821 2017 B nasopharynx healthy C078 
MPLM0822 2017 B nasopharynx healthy C079 
MPLM0832 2017 E nasopharynx healthy C086 
MPLM0833 2017 E nasopharynx healthy C087 





MPLM0837 2017 E nasopharynx healthy C089 
MPLM0838 2017 E nasopharynx healthy C090 
MPLM0087 2017 N lung dead C003 
MPLM0088 2017 N joint dead C003 
MPLM0093 2017 N lung dead C004 
MPLM0102 2017 N lung dead C005 
MPLM0103 2017 N joint dead C005 
MPLM0105 2017 N lung dead C006 
MPLM0106 2017 N joint dead C006 
MPLM0111 2017 N lung dead C007 
MPLM0112 2017 N joint dead C007 
MPLM0114 2017 N lung dead C008 
MPLM0145 2017 N lung dead C009 
MPLM0146 2017 N joint dead C009 
MPLM0148 2017 N lung dead C010 
MPLM0149 2017 N joint dead C010 
MPLM0154 2017 N lung dead C011 
MPLM0155 2017 N joint dead C011 
MPLM0157 2017 N lung dead C012 
MPLM0158 2017 N joint dead C012 
MPLM0160 2017 N lung dead C013 
MPLM0164 2017 N joint dead C014 
MPLM0054 2017 O lung dead C099 
MPLM0057 2017 O lung dead C100 
MPLM0058 2017 O joint dead C100 
MPLM0060 2017 O lung dead C101 
MPLM0061 2017 O joint dead C101 
MPLM0136 2017 S lung dead C132 
MPLM0824 2018 C nasopharynx healthy C081 





MPLM0827 2018 D nasopharynx healthy C083 
MPLM0828 2018 D nasopharynx healthy C084 
MPLM0830 2018 D nasopharynx healthy C085 
MPLM0533 2018 N lung dead C015 
MPLM0534 2018 N joint dead C015 
MPLM0538 2018 N joint dead C016 
MPLM0541 2018 N lung dead C017 
MPLM0542 2018 N joint dead C017 
MPLM0545 2018 N lung dead C018 
MPLM0546 2018 N joint dead C018 
MPLM0555 2018 N lung dead C019 
MPLM0556 2018 N joint dead C019 
MPLM0559 2018 N lung dead C020 
MPLM0560 2018 N joint dead C020 

















APPENDIX C – CHAPTER 4: MYCOPLASMA BOVIS ISOLATES 
Table A4.1. Summary of mycoplasma isolates discussed in Chapter 4. Isolates were derived 
from different anatomical locations (nasopharynx, lung, joint) from cattle with different health 
statuses (healthy, disease, dead) collected from feedlots A to Z from 2006 to 2018. The cattle 
identifer associated with each isolate is indicated, as more than one isolate was derived from a 















MPLM0632 2  2007 K nasopharynx dead C096 
MPLM0644 2  2007 Q nasopharynx diseased C104 




2017 E nasopharynx healthy C087 
MPLM0648 21  2006 J nasopharynx diseased C094 
MPLM0645 21  2007 Q nasopharynx diseased C105 
MPLM0662 21  2007 Q nasopharynx diseased C111 
MPLM0698 21  2007 Q nasopharynx healthy C118 
MPLM0706 21  2007 Q nasopharynx healthy C121 
MPLM0154 21 MJ287 2017 N lung dead C011 
MPLM0054 21 MJ260 2017 O lung dead C099 
MPLM0647 24  2007 Q nasopharynx diseased C106 
MPLM0657 24  2007 Q nasopharynx diseased C108 
MPLM0660 24  2007 Q nasopharynx diseased C109 
MPLM0661 24  2007 Q nasopharynx diseased C110 
MPLM0664 24  2007 Q nasopharynx diseased C112 
MPLM0666 24  2007 Q nasopharynx diseased C114 
MPLM0669 24  2007 Q nasopharynx dead C115 
MPLM0684 24  2007 Q nasopharynx healthy C116 
MPLM0692 24  2007 Q nasopharynx healthy C117 
MPLM0700 24  2007 Q nasopharynx healthy C119 





MPLM0715 24  2007 Q nasopharynx healthy C124 
MPLM0638 24  2015 I joint dead C055 
MPLM0541 27  2018 N lung dead C017 
MPLM0555 27  2018 N lung dead C019 
MPLM0556 27  2018 N joint dead C019 
MPLM0652 40  2007 Q nasopharynx diseased C107 
MPLM0665 40  2007 Q nasopharynx diseased C113 
MPLM0713 40  2007 Q nasopharynx healthy C122 
MPLM0667 40  2007 R nasopharynx healthy C126 
MPLM0668 40  2007 R nasopharynx healthy C127 
MPLM0640 42  2006 G nasopharynx healthy C091 
MPLM0649 42  2006 P nasopharynx diseased C102 
MPLM0642 42  2006 U nasopharynx diseased C134 
MPLM0670 42  2007 R nasopharynx healthy C128 
MPLM0671 42  2007 R nasopharynx healthy C129 
MPLM0636 42 MJ292 2014 S lung dead C074 
MPLM0634 42  2015 M lung dead C098 
MPLM0825 43  2018 C nasopharynx healthy C082 
MPLM0087 44 MJ267 2017 N lung dead C003 
MPLM0088 44 MJ268 2017 N joint dead C003 
MPLM0103 44 MJ272 2017 N joint dead C005 
MPLM0105 44 MJ273 2017 N lung dead C006 
MPLM0106 44 MJ274 2017 N joint dead C006 
MPLM0114 44 MJ278 2017 N lung dead C008 
MPLM0149 44 MJ286 2017 N joint dead C010 
MPLM0160 44 MJ289 2017 N lung dead C013 
MPLM0061 44  2017 O joint dead C101 
MPLM0815 45  2017 A nasopharynx healthy C075 
MPLM0832 45  2017 E nasopharynx healthy C086 
MPLM0136 45 MJ280 2017 S lung dead C132 
MPLM0827 45  2018 D nasopharynx healthy C083 
MPLM0828 45  2018 D nasopharynx healthy C084 





MPLM0631 52  2007 L joint dead C097 
MPLM0020 52 MJ246 2016 T joint dead C051 
MPLM0037 52 MJ255 2016 T lung dead C043 
MPLM0039 52 MJ257 2016 T lung dead C044 
MPLM0635 60 MJ291 2014 H lung dead C093 
MPLM0009 60 MJ237 2016 T lung dead C046 
MPLM0010 60 MJ238 2016 T joint dead C046 
MPLM0012 60 MJ240 2016 T joint dead C047 
MPLM0013 60 MJ241 2016 T lung dead C048 
MPLM0014 60 MJ242 2016 T joint dead C048 
MPLM0016 60  2016 T joint dead C049 
MPLM0017 60 MJ244 2016 T lung dead C050 
MPLM0018 60 MJ245 2016 T joint dead C050 
MPLM0025 60 MJ249 2016 T lung dead C052 
MPLM0026 60 MJ250 2016 T joint dead C052 
MPLM0031 60 MJ253 2016 T lung dead C053 
MPLM0035 60  2016 T lung dead C054 
MPLM0041 60 MJ258 2016 N lung dead C002 
MPLM0157 60  2017 N lung dead C012 
MPLM0533 60  2018 N lung dead C015 
MPLM0534 60  2018 N joint dead C015 
MPLM0538 60  2018 N joint dead C016 
MPLM0542 60  2018 N joint dead C017 
MPLM0545 60  2018 N lung dead C018 
MPLM0546 60  2018 N joint dead C018 
MPLM0559 60  2018 N lung dead C020 
MPLM0560 60  2018 N joint dead C020 
MPLM0015 61 MJ243 2016 T lung dead C049 
MPLM0703 62  2007 Q nasopharynx healthy C120 
MPLM0007 65 MJ235 2016 T lung dead C045 
MPLM0008 65 MJ236 2016 T joint dead C045 
MPLM0011 65 MJ239 2016 T lung dead C047 





MPLM0021 65 MJ247 2016 T lung dead C133 
MPLM0022 65 MJ248 2016 T joint dead C133 
MPLM0821 65  2017 B nasopharynx healthy C078 




2017 E nasopharynx healthy C090 
MPLM0093 67 MJ269 2017 N lung dead C004 
MPLM0102 67 MJ271 2017 N lung dead C005 
MPLM0111 67 MJ276 2017 N lung dead C007 
MPLM0112 67 MJ277 2017 N joint dead C007 
MPLM0145 67 MJ282 2017 N lung dead C009 
MPLM0146 67 MJ283 2017 N joint dead C009 
MPLM0155 67  2017 N joint dead C011 
MPLM0158 67 MJ288 2017 N joint dead C012 
MPLM0164 67  2017 N joint dead C014 
MPLM0057 67 MJ261 2017 O lung dead C100 
MPLM0058 67 MJ262 2017 O joint dead C100 
MPLM0060 67 MJ263 2017 O lung dead C101 
MPLM0629 70 MJ290 2007 Q nasopharynx diseased C103 
MP0079 70  2015 I lung dead C055 
MPLM0637 70 MJ293 2015 I lung dead C057 
MPLM0630 75  2008 K joint dead C095 
MP0209 76  2014 I joint dead C056 
MP0219 76  2014 I lung dead C056 
MPLM0003 77 MJ234 2016 F lung dead C072 
MPLM0004 77  2016 F joint dead C072 
MPLM0030 79 MJ252 2016 N joint dead C001 
MPLM0132 80  2016 S lung dead C130 
MPLM0134 80  2016 S lung dead C131 
MPLM0135 80  2016 S joint dead C131 









MPLM0643 151  2006 G nasopharynx healthy C092 
MPLM0822 152  2017 B nasopharynx healthy C079 
MPLM0823 153  2018 C nasopharynx healthy C080 












































APPENDIX D – ANTIMICROBIAL SUSCEPTIBILITY PLATE MAP 






































































































































































































Figure D1. Custom Sensititre™ plate for micro-dilution. Units are in µg/mL. ENRO, 
Enrofloxacin; TIP, Tildipirosin; GAM, Gamithromycin; TUL, Tulathromycin; FFN, Florfenicol; 
OXY, Oxytetracycline; CTET, Chlortetracycline; TIL, Tilmicosin; PEN, Penicillin; TYLT, 
Tylosin tartrate; and POS, Positive Control.
